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Abstract 
Background: Each year in the United States, about 54,000 women are diagnosed with ductal 
carcinoma in situ (DCIS). Most diagnoses are by screening mammography in asymptomatic 
women. Many women have small, low-grade lesions, and almost all are treated surgically. More 
than 50% of these women may be overdiagnosed. 
Objective: To characterize psychosocial harms of DCIS diagnosis and treatment. Understanding 
these harms might facilitate development of interventions to improve wellbeing in these women. 
Data Sources: MEDLINE, CINAHL, PsycINFO and Cochrane Library databases, reference lists, 
forward citation searches 
Study Selection: Studies evaluating psychosocial outcomes in adult women diagnosed and/or 
treated for DCIS were included. 
Data Extraction: Two reviewers assessed study quality using methods adapted from the United 
States Preventive Services Task Force and the Clinical Skills Assessment Programme. One 
reviewer abstracted data, and a second reviewer verified abstraction. 
Data Synthesis: Fifteen articles describing eight studies met inclusion criteria, including four 
prospective cohort studies, two cross-sectional studies, and two qualitative studies. Key findings 
include a clinically significant impact on quality of life in the first six months after diagnosis, and 
intrusive thoughts and fear of recurrence that commonly persist at least 18-24 months. 
Limitations: We include only a subset of the potential harms of DCIS. We do not consider 
studies of invasive breast cancers. Threats to internal validity included lack of power analyses, 
multiple statistical comparisons, and non-validated instruments. Few studies have assessed 
effects of diagnosis (labeling) independent of treatment. No studies meeting eligibility criteria 
have assessed interventions to improve wellbeing.  
Conclusions: Women with DCIS appear to experience clinically significant effects on wellbeing. 
Additional good quality longitudinal studies are needed to characterize the nature and burden of 
psychosocial harms experienced by these women.  
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Introduction 
Statement of Purpose 
Breast cancer is the most commonly diagnosed cancer in women apart from non-
melanoma skin cancers. An estimated 290,170 women will be diagnosed with invasive or in situ 
breast cancer in the United States in 2012.1 Approximately 54,000 (19%) of these cases will be 
ductal carcinoma in situ (DCIS, stage 0). 
A 2007 analysis suggested psychosocial aspects of breast cancer represent a critical 
gap in knowledge.2 For DCIS in particular, the National Institutes of Health (NIH) 2009 State-of 
the Science Statement identified “investigations of the impact of DCIS diagnosis and treatment 
on quality of life” and “data on patient perceptions” as key research areas.3 In line with these 
recommendations, we will systematically review the evidence regarding the psychosocial 
implications of DCIS diagnosis and treatment. We will consider psychosocial outcomes to 
encompass all aspects of a woman’s psychological, social, and emotional well-being, including 
relevant domains of global quality of life assessments.  
Some psychosocial consequences of invasive breast cancer diagnosis and treatment 
have been well described.4-6 Yet there appears to be a dearth of evidence about psychological 
outcomes specific to patients with DCIS. A 2010 narrative review by Ganz of the psychosocial 
and quality of life implications of DCIS described ten observational studies.7 Some of these 
studies suggest that the magnitude of distress experienced by women with DCIS may be similar 
to that seen in women with early invasive breast cancer (EIBC, stage I or II) who receive similar 
treatments but have poorer prognoses. However, many of these studies are limited by small 
sample size, use of non-validated instruments, and lack of a comparison to women without 
breast cancer. Ganz concluded that women with DCIS experience “substantial psychological 
distress”, but the precise nature and magnitude of these potential harms remains somewhat 
unclear.  
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 DCIS is most often diagnosed by screening mammography, and these women are 
promptly treated surgically.  As such, any psychosocial consequences are likely to be effects of 
the diagnosis (label) or treatment. Ganz highlights that both labeling and treatment likely 
contribute to psychosocial outcomes, but was largely unable to differentiate between these 
effects in her review.  
In this review, we systematically assess the burden of psychosocial harms of DCIS 
diagnosis and subsequent treatment. We examine the degree of psychosocial morbidity that 
might be attributed to a labeling effect independent of treatment. Finally, we search for studies 
of interventions to improve psychosocial outcomes in women with DCIS. We hope that a better 
understanding of potential harms, with identification of evidence gaps, will inform future 
research assessing the frequency and burden of psychosocial harms of DCIS diagnosis and 
treatment. In time, a better categorization of potential morbidities might aid in the development 
of strategies to mitigate these harms.  
Ductal Carcinoma in Situ: Epidemiology, Prognosis, and Treatment 
The development and application of screening mammography led to an increase in 
DCIS detection beginning in the early 1980’s. Most often, imaging identifies small low-grade 
lesions.8 From 1975 to 2004, the incidence increased from 5.8 to 32.5 cases per 100,000 
women per year, a 460% relative increase.9  Today, DCIS accounts for approximately 19% of all 
new breast cancer diagnoses, and 25% of those detected by screening mammography.10 Risk 
factors appear to be similar to risk factors for developing invasive cancer, including family 
history, increasing age, and older age at first childbirth.8,11 
Women with DCIS are at some increased risk of developing invasive disease. However, 
the natural history of DCIS is poorly understood, and is difficult to elucidate because patients 
are almost always treated surgically.8 Small retrospective cohort studies of women with 
untreated DCIS suggest that a substantial portion (>50%) would not develop invasive breast 
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cancer with extended follow-up (>10 years), but the precise proportion of lesions that would 
eventually progress remains uncertain.12,13 
Treatment of DCIS is similar to treatment of early invasive breast cancer. Mastectomy is 
sometimes performed, but most women are candidates for breast conserving therapy (BCT), 
consisting of wide local excision with or without radiation therapy. The presence of multi-centric 
disease is often considered a contraindication to breast-conserving therapy, though some argue 
that BCT may be an option as long as negative margins can be obtained with a cosmetically 
acceptable excision.8,14 Some women undergo contralateral prophylactic mastectomy, but no 
survival benefit has been shown and it is generally not recommended.15 
Breast cancer-specific mortality appears to be 1-2% over 8-10 years with surgical 
treatment.16,17 Women who opt for local excision with radiation are more likely to experience 
local recurrence of DCIS, but long term breast cancer mortality is equivalent in women treated 
by BCT as compared to mastectomy.8 At least for women over the age of 67, life expectancy 
appears to be the same in those treated for DCIS compared to the general population.18 
Ductal Carcinoma in Situ: Harms 
It is imperative to examine the balance of potential harms and benefits of everything we 
do in medicine. This balance might be examined along the entire screening cascade, from the 
decision to screen for breast cancer, to treatment and follow-up for DCIS. Some proportion of 
women who undergo screening will inevitably go on to be diagnosed with DCIS and potentially 
experience harms of DCIS diagnosis and treatment.  
Psychosocial Harms 
 Psychosocial outcomes have been studied more extensively for invasive breast cancer 
than for DCIS. Invasive breast cancer is associated with impaired health-related quality of life.4 
Breast cancer patients are at increased risk of experiencing anxiety.5 Prevalence of cancer-
related post-traumatic stress disorder (PTSD) appears to be between 3% and 10% even years 
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after diagnosis.19-21 About 70% of breast cancer survivors are fearful that their illness will 
return.22 Almost all of these studies have examined cancer patients who have begun or 
completed treatment, so it is impossible to attribute poor outcomes exclusively to the experience 
of a cancer diagnosis or to the effects of treatment.  
In some cases, it may be reasonable to extrapolate what we know about women with 
early invasive cancers to make conjectures about these same outcomes in women with DCIS. 
However, since DCIS and EIBC may differ by clinical symptoms, prognosis, and treatment 
modalities, we rely on studies of women with DCIS for this review.  
Labeling 
Certain psychosocial consequences of DCIS might relate to the diagnosis itself. The 
term DCIS includes the word “carcinoma”, and women are often told that they have an early 
breast cancer. A “label” of breast cancer might affect the way women view themselves, or the 
way they are viewed by those around them. They may experience fear and uncertainty 
regarding anticipated difficult treatments and poor health, and might worry in particular about the 
possibility of death. As with all harms, these consequences may range in severity and duration, 
from mild and transient to severe and prolonged. 
Few studies have looked at the psychosocial effects of invasive breast cancer diagnosis 
prior to commencing treatment. In a cross-sectional study of 236 stage I-III breast cancer 
patients presenting for pre-surgical consult, Hegel et al. found that 41% had clinically significant 
distress.23 Prevalence of major depression was 11%, and 10% met criteria for PTSD. Emotional 
symptoms interfered with daily functioning for these women. As part of this review, we will ask 
whether women with DCIS, who have a very good prognosis, experience this same degree of 
distress in the period between diagnosis and treatment.  
In their 2009 DCIS Consensus Statement, the NIH suggested that consideration be 
given to “remove the anxiety-producing term ‘carcinoma’ from the description of DCIS” given the 
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condition’s favorable prognosis.24 They also identified “research on patient-provider 
communication and development of decision aids with assessment of their impact on quality of 
care” as another critical research area. But they do not cite any evidence that the term DCIS 
does in fact cause patients to experience anxiety, or that careful framing of the diagnosis might 
alleviate anxiety. As such, it remains unclear whether interventions to improve psychological 
outcomes and quality of life in women with DCIS should specifically target the way we 
communicate about DCIS.  
Treatment 
The burden of physical effects of cancer or its treatment may also contribute to 
psychosocial morbidity.25 Since DCIS is most often screen-detected and promptly treated, we 
assume that treatment effects are more likely to affect these outcomes than physical cancer 
symptoms. A given treatment modality might be expected to affect a woman with DCIS similarly 
to a woman with invasive cancer, but the modalities received often vary by stage.  
There is a substantial body of literature examining psychosocial harms of invasive breast 
cancer treatment. Women may experience persistent problems with body image and sexual 
functioning after mastectomy. In randomized controlled trials comparing mastectomy to BCT, 
mastectomy appears to be associated with greater pre-treatment and post-treatment anxiety, 
particularly in the first year after treatment.5 Women who undergo axillary procedures, especially 
axillary lymph node dissection, are more likely to report lymphedema and other arm symptoms; 
and women who experience these symptoms have poorer physical and mental health-related 
quality of life.26,27 Chemotherapy and hormonal therapy also have a negative impact on quality of 
life.4  
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The Big Picture 
 There are other potential harms of DCIS that we will not consider, such as physical 
effects of treatment and financial burden. Labeling effects might also go beyond psychosocial 
harms, for example, if labeled women alter behavior in ways that are harmful to their health. 
Many of the women diagnosed by mammography are overdiagnosed, meaning they would not 
have experienced harmful effects of breast cancer during their lifetime in the absence of 
screening. Rates of overdiagnosis in DCIS might be higher than 50%, but it is impossible to 
predict which women have been overdiagnosed.28 
All of these potential harms might be considered in the broader context of breast cancer 
screening. Close examination of the balance of benefits and harms may be particularly 
important for women ages 40-49. In these women, the United States Preventive Services Task 
Force (USPSTF) has determined that there is only a small net benefit of screening, and the 
decision to screen should take into account patient values regarding benefits and harms.6 
Summary 
Ductal carcinoma in situ has become increasingly prevalent since the advent of 
widespread screening mammography. Approximately 54,000 women will be diagnosed in 2012, 
and an estimated one million women will be living in the United States with DCIS by 2020.1,29  
This systematic review attempts to clarify what is known about the potential effect of 
DCIS diagnosis and treatment on a woman’s wellbeing. We hope that a systematic approach to 
this question will allow us to more precisely define the strength of the existing evidence, and 
more clearly elucidate what questions remain to be answered. A better understanding of 
potential harms, with identification of evidence gaps, may inform future research assessing the 
burden of these psychosocial harms and the development of strategies to mitigate these effects. 
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Methods  
Prior to undertaking this systematic review, we performed a literature search for previous 
systematic reviews of this topic. We identified the narrative review by Ganz in 2010, but did not 
identify any systematic reviews.7 In our review, we considered studies included by Ganz, and 
included them only if they met our eligibility criteria. In accordance with the PRISMA checklist for 
reporting systematic reviews, we report our systematic search of the literature, assessment of 
the quality and generalizability of relevant studies, and estimation of the strength of evidence.30 
Specifically, we aim to answer the following key questions:  
Key Question 1 (KQ1): Among adult women, what are the psychosocial effects of being 
diagnosed with, and subsequently treated for, DCIS?  
Key Question 2 (KQ2): To what degree are these effects attributable to the DCIS diagnosis, or 
label, independent of treatment?  
Key Question 3 (KQ3): What interventions, if any, have been shown to improve psychosocial 
outcomes in women with DCIS? 
Eligibility Criteria: 
We prospectively defined broad inclusion criteria to provide a complete picture of the 
literature. We used a single search strategy and set of eligibility criteria for all of our key 
questions.  
We accepted only peer-reviewed studies available in full text. Cohort, case-control, and 
cross-sectional studies, randomized controlled trials (RCTs), systematic reviews, and qualitative 
studies were eligible for inclusion. We excluded case reports and nonrandomized trials, as well 
as non-peer-reviewed literature. The complete PICOTS framework for study inclusion is 
presented in table 1.  
We included women over the age of 18 of all ethnicities. We considered only studies 
conducted in OECD (Organization for Economic Cooperation and Development) nations in 
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order to limit results to settings where detection by mammography and treatment for DCIS are 
likely to be available.  
We required that median time from diagnosis (or from initial treatment) be less than 
three years. A number of studies suggest that women experience moderate to high levels of 
psychological distress in the first year after breast cancer diagnosis, and that this distress may 
generally decrease over time.31 By limiting to three years from diagnosis, we hoped to include 
the time period during which women were most likely to experience adverse psychosocial 
consequences of DCIS diagnosis and treatment. We excluded studies with no indication of time 
from diagnosis or initial treatment and studies that do not report treatment history.  
We included studies of women diagnosed with DCIS whether they are pre- or post-
treatment. Post-treatment studies include women that have been exposed both to labeling and 
treatment effects (KQ1), whereas pre-treatment studies might isolate the psychosocial effects of 
labeling (KQ2). Alternatively, studies might attempt to separate labeling effects from treatment 
effects by comparing women who have received different diagnoses (for example: DCIS vs. 
EIBC) but the same treatment (say, mastectomy). We included studies with or without an 
intervention that might mitigate potential psychosocial harms (KQ3). 
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Table 1. PICOTS Framework for Psychosocial Outcomes in DCIS 
  
Category Inclusion Criteria 
Population Women with DCIS, any ethnicity, >18 years 
Intervention No intervention required (KQ1 and KQ2) 
All interventions included (KQ3) 
Comparators Cross-sectional and case-control studies 
 Women with EIBC 
 Healthy controls 
o Average risk or high risk women 
 No comparator, if correlates of 
outcomes are examined  
Cohort studies, qualitative studies, and RCTs:   
 Accept studies of DCIS only 
Outcomes  Any psychosocial outcomes, including: 
 Anxiety 
 Depression 
 Worry 
 Fear 
 Intrusive thoughts 
 Sexual dissatisfaction  
 Body image disturbance 
 Perceived risk (of recurrence or 
mortality) 
 Quality of life 
Timing of Effect  Within 36 months of diagnosis 
 Or <36 months from initial treatment  
 May be pre- or post- treatment 
Timing of Search 1990 to present 
Setting Any setting, limited to OECD nations 
Study Designs  Systematic reviews 
 Cohort studies 
 Case-control studies 
 Cross-sectional studies 
 Qualitative studies 
 Randomized controlled trials (KQ3) 
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We considered relevant comparators to include either healthy controls or women with 
early invasive breast cancer (EIBC). We excluded more advanced breast cancers because of 
the dramatically different clinical presentation, prognosis, and treatment.  
Longitudinal studies with no comparison group were included because of what they 
might tell us about how these measures change with time. We included cross-sectional studies 
that compared scores on validated scales to ‘population norms’. Finally, to assess risk factors 
for poor psychosocial outcomes, we accepted single arm cross-sectional studies that report 
relevant outcomes by treatment modality or other hypothesized correlates. We otherwise 
excluded cross-sectional studies with no comparison group.  
We required that single arm studies include at least 50 participants with DCIS. For 
multiple arm studies, we required that each arm include at least 25 participants. We did not 
require a minimum sample size for qualitative studies.  
We included studies reporting at least one psychosocial outcome in women diagnosed 
with DCIS. Many studies of invasive breast cancer include women with DCIS, but we only 
included studies that report outcomes specifically for women with DCIS.  
We included any outcome related a woman’s wellbeing following diagnosis or treatment 
of DCIS. We derived a list of likely relevant psychosocial outcomes from the narrative review by 
Ganz and a systematic review by Salz et al. examining the effects of false positive 
mammograms.7,32 These outcomes, used to develop our search strategy, included anxiety, 
depression, worry, fear, intrusive thoughts, risk perception, and quality of life. Risk perception 
could refer to perceived likelihood of local, contralateral or distant DCIS or invasive recurrence, 
or of breast cancer mortality. For quality of life, we highlight emotional and psychological 
domains in our analysis. Other outcomes not included in our initial list, but considered relevant 
during study selection, included sexual dissatisfaction and body image disturbance. 
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Knowledge of disease process and patient satisfaction were considered beyond the 
scope of this review. We excluded purely physical symptoms such as pain or hot flashes, but 
recognize that side effects of treatment and physical symptoms of disease may influence 
included outcomes.  
 We accepted ad hoc and previously validated measures, but incorporated validity and 
reliability of measures into our quality assessment tool. Both disease-specific and generic 
measures were considered, although we expected disease-specific measures to be more 
sensitive to small, yet clinically important differences.32 
Data Sources and Searches  
Two reviewers independently searched the MEDLINE, CINAHL, PsycINFO and Cochrane 
Library databases for relevant articles. All searches were limited to studies published from 
January 1, 1990 through April 20, 2012. Studies published in languages other than English were 
not considered due to limited resources. The selected time period was intended to capture 
studies published since DCIS incidence began increasing in association with the widespread 
use of screening mammography.16 
Our MEDLINE search crossed a series of diagnosis terms with keywords representing 
outcomes of interest. Diagnosis terms included the Medical Subject Heading (MeSH term) 
“Carcinoma, Intraductal, Noninfiltrating” and the keyword “ductal carcinoma in situ”. We 
recognized that some relevant studies might stratify breast cancer patients by stage without 
using the term DCIS. Thus, we also crossed the MeSH term “Breast Neoplasms” and keyword 
“breast cancer” with “in situ”, noninvasive, and “stage 0”.i We accepted noninvasive or stage 0 
breast cancer as proxies for DCIS since the majority these women have DCIS.  
Outcomes keywords included anxiety, depression, distress, worry, fear, “perceived risk”, 
“risk perception” and “quality of life”. Complete search strings are presented in appendix B.  
                                                          
i
 Subsequent to our initial search, we added the term “stages 0” because we missed studies (including one cited by 
Ganz) that presented the study population as, say, women with breast cancer “stages 0-II”.  
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Study Selection 
Titles and abstracts of all identified studies were imported into a RefWorks 2.0 citation 
database (Proquest LLC), and duplicates were excluded. Two reviewers independently 
reviewed all titles and abstracts and excluded studies that they agreed did not meet eligibility 
criteria. If either reviewer felt the article might meet criteria, it was included in subsequent full 
text review. When we identified multiple reports examining the same study population, we 
considered them together. 
During full text review, the two reviewers independently determined whether the studies 
satisfied eligibility criteria. We did not attempt to contact authors to obtain additional data. 
Disagreements about inclusion or exclusion were resolved by consensus of the two reviewers. If 
any disagreement remained, the dispute was resolved by a third, senior reviewer.  
In addition, reference lists of all included studies were hand searched for other studies 
meeting eligibility criteria. We used Google Scholar to search forward in time for studies that cite 
included articles. The same methods for title and abstract review, and subsequent full text 
review, were used for these studies.  
Data Extraction and Assessment of Validity 
One reviewer (WR) extracted study characteristics and results and summarized these 
data in evidence tables. A second reviewer checked the data extraction for consistency, and 
discrepancies were resolved by consensus.  
For observational studies and RCTs, we used an internal validity (risk of bias) 
assessment tool adapted from Berkman et al. and the USPSTF (Appendix B).33 We assessed 
validity at the level of outcomes. Two reviewers independently assigned a rating of good, fair, or 
poor for each internal validity criterion. Disagreements were resolved by consensus among the 
two reviewers. 
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The assessed criteria were: randomization and allocation concealment (RCTs only), 
creation and maintenance of comparable groups, measurement of exposure and outcomes, 
appropriate statistical analyses, consideration of confounding, and adequate sample size. From 
these criteria, the reviewers assigned an overall quality rating for each study of good, fair, or 
poor. We considered good quality studies to be those meeting standards for good quality in 
nearly all criteria (two fair ratings and no poor ratings permitted). We generally considered 
studies with two or more poor criteria ratings, or one major flaw likely to invalidate results, to be 
poor overall quality. Poor quality studies were excluded from further review.  
Appropriate quality appraisal combines subjective and objective assessments. By using 
the appraisal tool, we largely standardized quality assessment across studies. Certain criteria, 
such as whether participants were adequately described or confounding adequately controlled, 
did entail subjective assessment. We introduced an additional degree of subjectivity in 
determining what constitutes a big enough flaw to invalidate the study results.  
We used a similar process to assess the credibility of qualitative studies. Credibility was 
assessed by two reviewers using a tool adapted from the Critical Appraisal Skills 
Programme.34,35 Studies were assessed for appropriate description of sampling, data collection, 
reflexivity, data analysis, and findings. An overall rating of good, fair, or poor credibility was 
assigned, and poor credibility studies were excluded. Appendix B includes the complete tool, 
with detailed methods for assigning these ratings. 
The external validity of individual studies was determined using criteria adapted from the 
United States Preventive Services Task Force (USPSTF).36 Studies were rated “good” if the 
study population differed minimally from a typical population of adult women diagnosed with 
DCIS derived from a typical primary care setting. In this case, it is considered highly probable 
(>90%) that the results are applicable to broader populations of women with DCIS. External 
validity was rated as “poor” if the study population differed from typical populations of women 
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with DCIS in many ways that have a high likelihood of affecting clinical outcomes. Other studies 
were considered to have “fair” external validity. In determining external validity, we considered 
the study setting, population characteristics, participation rate, and other elements that might 
affect the degree to which the study population is similar to a broader population of DCIS 
patients. To promote transparency in light of the subjectivity of the external validity ratings, we 
highlight the study aspects that we considered significant detractors from external validity. We 
used similar methods to evaluate the transferability of qualitative studies.  
Data Synthesis 
 We performed qualitative data synthesis, organizing results by the specific outcome 
reported. Given the inconsistency of instruments used to measure each outcome, meta-analysis 
was not possible. We did not attempt to assess for publication bias.  
As described by Owens et al, we graded the overall strength of evidence for outcome as low, 
moderate, high, or insufficient, based on risk of bias, consistency, directness, and precision of 
findings.37 These methods are described in detail in Appendix B. 
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Results 
A flow diagram of the results of our search strategy and study selection process is 
shown in Figure 1 according to PRISMA recommendations.30 A total of 361 studies were 
identified through searches of the MEDLINE, PsycINFO, CINAHL, and Cochrane Library 
databases. We identified 629 additional articles by hand-searching the reference lists of 
included studies, and 367 articles by forward citation searches of included studies using Google 
Scholar. After removal of 309 duplicates, 1048 titles and abstracts were screened. We excluded 
983 at the title and abstract stage, and we reviewed the full text of the remaining 68 articles.  
We excluded 53 articles during full text review. Five were not peer-reviewed literature, 
35 were primarily studies of invasive breast cancer and/or did not report outcomes specific to 
DCIS, and seven did not meet other PICOTS criteria. We excluded six studies for poor quality. 
We list these studies, with reasons for the poor quality rating, in Appendix C, Table 2.  
A total of fifteen articles describing eight unique studies met all eligibility criteria and 
were included in the final systematic review. We describe how our list of included studies 
compares to the list included by Ganz in Appendix C. 
Description of Included Studies 
 Characteristics of included studies are summarized in Evidence Tables 1 and 2. The 
eight studies examined a total of 2,186 women with DCIS. We included four prospective cohort 
studies, two cross-sectional studies, and two qualitative studies. One of the qualitative studies 
(Kennedy et al.) interviewed a cohort of women at multiple time points after diagnosis; we will 
refer to this as a “serial qualitative” design.38 
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Figure 1. Study Flow Diagram 
 
 
*Of fifteen included articles, thirteen were identified by database searches, one by hand-searching reference lists of 
included studies, and one by forward citation searching. 
 
 
 
Comparators 
Of the six included observational studies, three compared women with DCIS to women 
with invasive breast cancer, one compared women with DCIS to women with no breast 
diagnosis, and one included both women with invasive cancers and healthy controls. One of the 
cohort studies and the two qualitative studies included only women with DCIS. Only two studies 
(Nekhlyudov et al. and Partridge et al.) included pre-diagnosis assessments of women who later 
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developed DCIS.39,40 The pre-diagnosis assessment in Partridge et al. was recalled at study 
enrollment, after DCIS diagnosis. 
Treatment Status and Key Questions 
Six of the eight studies included only patients that had competed surgical treatment 
(primarily KQ1). One qualitative study (Kennedy et al.) included some women between 
diagnosis and surgical treatment.38 The first post-diagnosis time point of Partridge et al. included 
some women who had not yet been treated, but results are not reported specifically for these 
women.40 
Several studies indirectly examine psychosocial outcomes independent of treatment 
history by controlling for treatments received as potential confounders (KQ2). We found no 
studies meeting eligibility criteria that tested interventions to mitigate psychosocial harms of 
DCIS diagnosis and treatment (KQ3). 
Outcome Assessment 
The qualitative studies broadly examined the experience of women receiving DCIS 
diagnosis and treatment. Most of the observational studies assessed one or two psychosocial 
outcomes. These outcomes included: anxiety, depression, intrusive thoughts, body image, 
sexual problems, overall psychological distress, fear of recurrence, risk perception, and quality 
of life.  One group has reported six different psychosocial outcomes for one cohort over seven 
publications (most recently Jeffe et al.).41-47 Both disease-specific and generic measures have 
been reported. The instruments used, and the degree to which they have been validated, are 
described in Evidence Table 1. 
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Evidence Table 1. Characteristics of Included Studies 
Study Design Population 
Sample 
Size 
Treatment History 
Timing of 
Assessment 
Outcomes 
Constructs 
Outcome 
Measures 
Clinically Important 
Results 
Previously 
Validated? 
Bailey et 
al.,    
2010
41-47
 
Liu, Pérez, 
Schootman 
et al., 2010 
Liu , Pérez 
Aft et al., 
2010 
Pérez et al., 
2010 
Collins et 
al., 2011 
Liu et al., 
2011 
Jeffe et al., 
2012 
Prospective 
cohort 
Cases of DCIS, 
Stage I, stage 
IIA, or screen 
negative age-
matched controls 
at two academic 
centers in St. 
Louis, Missouri, 
2003 to 2007 
DCIS       
n = 184 
EIBC        
n = 365 
Controls  
n = 547 
DCIS 
40% mastectomy 
44% lymph node 
removal 
56% radiation 
0% chemotherapy 
43% hormone 
therapy 
 
EIBC 
33% mastectomy    
(29% of stage I,    
50% of stage IIA) 
98% lymph node 
removal 
67% radiation 
37% chemotherapy 
73% hormone 
therapy 
7 weeks, 
6 months, 
12 months, 
24 months 
From surgery 
or screening 
mammogram 
Depression CES-D 
>15 suggests 
moderate to severe 
depression 
Yes 
Fear of 
recurrence 
CARS 
Score of 3-4 
suggests moderate 
fear 
Score of 5-6 
suggests high levels 
of fear 
Partially 
validated
48
 
Body image 
New 8 item 
questionnaire 
Not specified 
Adapted from 
validated 
instruments 
Sexual 
problems 
New 9 item 
questionnaire, 
2 subscales 
Not specified 
No, partially 
validated by 
Pérez et al. 
Risk 
perception 
 
Absolute (%) 
risk of 
recurrence 
Accuracy by 
comparison to 
Adjuvant! 
Online 
estimation 
Not specified No 
Quality of life 
Medical 
Outcomes 
Study    
RAND-36 
3-5 point change on 
one subscale 
Yes 
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Study Design Population 
Sample 
Size 
Treatment History 
Timing of 
Assessment 
Outcomes 
Constructs 
Outcome 
Measures 
Clinically Important 
Results 
Previously 
Validated? 
Janz et al., 
2005
49
 
Cross-
sectional 
Consecutive 
cases of DCIS 
and 20% random 
sample of EIBC 
from Detroit and 
Los Angeles 
SEER sites, 
2001 to 2003 
DCIS       
n = 555 
Stage I      
n = 462 
Stage II     
n = 239 
68% BCS,             
18% mastectomy, 
13% mastectomy with 
reconstruction,      
18% chemotherapy, 
57% radiation, 52% 
hormone therapy 
Women with DCIS 
and Stage I more 
likely to get BCS 
Women with DCIS 
more likely to get 
breast reconstruction, 
less likely to get 
chemotherapy 
7 weeks 
(mean) after 
completing  
treatment 
 
 
 
Health-related 
QOL 
 
 
 
EORTC QLQ-
C30 
 
>10 point difference 
suggests moderate 
change 
 
Yes 
Breast cancer-
specific QOL 
QLQ BR-23 
>10 point difference 
set as clinically 
meaningful 
Yes 
Janz et al., 
2009
50
 
Cross-
sectional 
Consecutive 
African American 
and Hispanic 
cases, random 
sample of white 
women, with 
DCIS, Stage I, 
Stage II, or Stage 
III from Detroit 
and Los Angeles 
SEER sites, 
2005 to 2007 
DCIS       
n = 272 
Stage I    
n = 593 
Stage II   
n = 459 
Stage III 
n = 168 
Overall 
80% lumpectomy, 
20% mastectomy 
89% radiation,        
50% chemotherapy 
9 months 
(mean) after 
diagnosis 
Breast cancer-
specific QOL 
FACT-B Not specified Yes 
Lauzier et 
al., 2009
51
 
Prospective 
cohort 
Consecutive 
cases of DCIS or 
non-metastatic 
invasive breast 
cancer at 8 
Quebec 
hospitals, 2003 
DCIS       
n = 107 
Invasive 
n = 693 
DCIS 
90% BCS,             
94% no axillary 
procedure, 0% 
chemotherapy, 40% 
hormone therapy,                 
84% radiotherapy 
Invasive 
78% BCS, 78% 
axillary dissection,             
54% chemotherapy, 
7% radiotherapy,   
80% hormone 
therapy 
1 month, 
6 months, 
1 year 
From initiation 
of treatment 
Psychological 
distress 
(generic, 
primarily 
anxiety and 
depression 
symptoms) 
14 item PSI 
Evaluated by effect 
size 
0.5 considered 
minimally important 
difference 
Yes 
Quality of life 
(mental health, 
including 
effects on daily 
functioning) 
MOS SF-12 
MCS 
Evaluated by effect 
size 
0.5 considered 
minimally important 
difference 
Yes 
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Study Design Population 
Sample 
Size 
Treatment History 
Timing of 
Assessment 
Outcomes 
Constructs 
Outcome 
Measures 
Clinically Important 
Results 
Previously 
Validated? 
Nekhlyudov 
et al., 
2006
39
 
Prospective 
cohort 
DCIS patients 
and controls from 
Nurses’ Health 
Study 
DCIS       
n = 510 
Controls    
n= 
114,218 
DCIS 
54% lumpectomy, 
38% mastectomy,   
8% unknown 
41% radiation 
34% tamoxifen 
1992, 
1996, 
2000 
Analyzed by 
time from 
diagnosis 
Quality of life MOS SF-36 
>10 point difference 
considered clinically 
meaningful 
Yes 
Partridge et 
al., 
2008
40,52
 
de Moor et 
al., 2010 
Prospective 
cohort 
Consecutive 
cases at 
academic and 
community 
hospitals in 
Eastern 
Massachusetts, 
2000 to 2004 
DCIS                
n = 487 
13% missing 
 
Mastectomy 
30% yes, 57% no 
 
Tamoxifen 
38% yes, 50% no 
 
Radiation 
43% yes, 44% no 
Pre-diagnosis 
(recalled) 
 
At enrollment 
(mean 5.5 
months from 
Dx, pre or 
post-Rx) 
 
9 months 
 
18 months 
 
Anxiety 
 
14 item HADS 
>10 on anxiety 
subscale suggests 
substantial anxiety 
Yes 
Depression 
14 item HADS 
>10 on depression 
subscale suggests 
depression 
Yes 
CES-D 
>15 suggests mild to 
moderate 
depression 
Yes 
Intrusive or 
avoidant 
thoughts 
15 item RIES, 
DCIS-specific 
>11 suggests 
substantial intrusive 
or avoidant 
thoughts,                  
> 25 suggests 
moderate Sx               
> 43 suggests 
severe Sx 
Adapted from 
validated 
instrument 
Quality of life 
 
MOS SF-36 
 
<50 is poor for 
mental component 
subscale 
Yes 
Risk 
perception 
Absolute (%) 
and likert-
scales 
 
Not specified 
 
Adapted from 
non-validated 
instrument 
 
Note: When multiple articles have been published about the same study population, these articles are presented together. 
Abbreviations: DCIS, ductal carcinoma in-situ; EIBC, early invasive breast cancer; CES-D, center for epidemiologic studies depression scale; CARS, concern about cancer 
recurrence scale; SEER, surveillance, epidemiology, and end results; BCS, breast-conserving surgery; QOL, quality of life; EORTC QLQ-C30, European organization for the 
research and treatment of cancer quality of life questionnaire; QLQ BR-23, breast cancer-specific quality of life questionnaire; FACT-B, functional assessment of cancer therapy-
breast; PSI, psychiatric symptom index; MOS SF-12 MCS, medical outcomes study short form health survey, mental component summary; HADS, hospitalized anxiety and 
depression scale; RIES, revised impact of event scale; Sx, symptoms 
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Evidence Table 2. Characteristics and Results of Qualitative Studies 
 
Study Design Study Population Results Credibility Transferability 
De Morgan et al., 
2002
53
 
Qualitative, 
focus group 
interviews 
n = 26 
Consecutive DCIS diagnoses of select 
breast cancer specialists 
>6 months from diagnosis (2/3 < 1 year) 
21 from Sydney, Australia 
5 from rural Australia 
“Most women reacted with shock to their diagnosis” 
Confusion about whether they had cancer, ranging from no 
concern about spread, to concern about metastases 
Dissatisfaction with the amount of information about DCIS 
Concern that mastectomy might be ‘overreacting’ 
Fair 
Poor 
 
Convenience 
sample 
Australia 
>10 years ago 
Select group of 
specialty practices 
Kennedy et al., 
2011
38
 
Qualitative, 
serial semi-
structured 
interviews  
n = 45 at initial interview, mean 38 days 
from diagnosis 
n = 27 at 9-13 month follow-up 
DCIS cases from 9 breast clinics in the 
United Kingdom 
20 pre-surgery and 25 post-surgery 
DCIS experiences merged and sometimes conflicted with 
beliefs about invasive breast cancer 
 
Labeling: Many felt relief regarding the good prognosis 
Significant confusion about whether DCIS is ‘cancer’, and 
the need for mastectomy or adjuvant treatments for a    
‘pre-cancer’  
One woman reported “discrimination from insurance 
companies… and time off work” and loss of her career 
Before treatment, women described anxiety, disbelief, 
intrusive thoughts. “lying in bed thinking I’m riddled with it” 
 
Treatment: Some report unexpected side effects of 
surgery. One expressed regret and a loss of confidence 
after mastectomy 
Mixed emotions immediately after surgery. Some guilt, 
shame, anger. Some report “sailing through treatment”. 
Others report fatigue, discomfort and other physical 
difficulties 
 
Concern about ongoing risk ranging was common, from 
fleeting concerns to intrusive thoughts. “vulnerability” 
Fair 
Fair 
 
Convenience 
sample 
White, English-
speaking women in 
the UK 
 
 
Note: Transferability rating is largely a subjective determination. Reasons for not being rated as ‘good’ applicability are described here. 
Abbreviations: DCIS, ductal carcinoma in situ; UK, United Kingdom;  
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Validity of Included Studies 
 Internal validity and credibility assessments of included studies are summarized in 
Appendix C, Tables 3 and 4. Three studies were rated as good quality (Jeffe et al., validated 
outcomes only, Janz et al., 2005, and Nekhlyudov et al.).39,47,49 Among observational studies, 
common limitations to internal validity included a lack of power analyses to ascertain an 
adequate sample size (0/6 studies), and inadequate baseline description of participants by 
stage (3/6 studies). Three studies assessed for numerous statistical relationships without a 
priori hypotheses or adjustment for multiple comparisons. Both studies that assessed risk 
perception used ad hoc measures whose validity has not been examined. Finally, we 
considered the recalled pre-diagnosis outcomes in Partridge et al. to have poor internal validity 
because of the potential for substantial recall bias.  
 External validity assessment is summarized in Appendix C, Table 5. All six observational 
studies were rated as fair external validity. Participation rates among invited individuals were 
less than 75% for all but one study. Participants and non-participants tended to differ in race 
and age. Some studies were performed in specific clinical or geographic settings. Nekhlyudov et 
al. was completed more than ten years ago and may not be entirely be generalizable to women 
with DCIS today.39  None of these factors are necessarily detrimental to generalizability, but we 
considered them sufficient to preclude any study from being rated as good external validity. 
 Both qualitative studies were rated as having fair credibility. Neither qualitative study 
used purposive sampling, adequately explored potential biases, or considered alternative 
explanations of results. De Morgan et al. was rated as poor transferability given that it examined 
a convenience sample of Australian women more than ten years ago (Evidence Table 2).53 
Kennedy et al. studied a more recent convenience sample of women with DCIS in the UK, and 
was rated as fair transferability. 38 
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Results for Key Question 1 – Effects of Diagnosis and Treatment 
Study results, with estimations of strength of evidence, are summarized in Evidence 
Table 3. Complete results are described in Appendix C, Evidence Tables 4 and 5. 
Quality of Life 
Two good quality cohort studies provide a moderately strong evidence base regarding 
generic quality of life measures in the first six months after DCIS diagnosis and treatment. Jeffe 
et al., published in 2012, demonstrated lower QOL in women with DCIS relative to healthy 
controls at 7 weeks from diagnosis.47 This difference was clinically significant and was 
consistent across all QOL domains. Nekhlyudov et al. supports an early decrement in quality of 
life by demonstrating that clinically important declines in QOL, particularly in the ‘mental health’ 
and ‘social function’ domains, were more likely in women who were less than six months from 
diagnosis compared to women more than six months from diagnosis.39 
More than six months from DCIS diagnosis, generic quality of life appears approximately 
equal to women with no breast diagnosis. Quality of life in women with DCIS compared to 
women with EIBC varied by domain, but appears to be somewhat better in women with DCIS 
throughout the first two years.  
Intrusive Thoughts, Fear of Recurrence, and Risk Perception 
 One fair quality prospective cohort (Partridge et al.) estimated that, at 7 weeks, 53% of 
women with DCIS experience substantial avoidant or intrusive thoughts relating to their 
diagnosis.40 At 18 months, 31% of women continued to experience these symptoms. Similarly, 
29% of women with DCIS in a fair quality cross-sectional study (Liu et al.) experienced at least 
moderate fear of cancer recurrence two years after diagnosis.46 More than half of women 
treated for DCIS believed they are at least moderately likely to develop invasive breast cancer, 
despite very low actual risk (Partridge et al.).40  
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Anxiety and Depression 
 Prevalence of depression in two cohort studies of women with DCIS was 2% and 10% 
respectively, and did not change significantly over time. One good quality cohort study 
compared incidence of depression in women with DCIS compared to healthy controls and found 
no difference.41  One fair quality cohort study found similar results for prevalence of clinically 
significant anxiety, which was consistently about 10% during the first year after diagnosis.40  
Body Image and Sexual Problems 
 One prospective cohort study examined body image and sexual problems by breast 
cancer stage.44,45 Women who had BCT had slightly better body image than women who had a 
mastectomy. Sexual problems appeared to increase over time for women who underwent 
mastectomy. No differences were observed by stage of disease. 
Qualitative Studies 
 Selected results from qualitative studies are described in Evidence Table 2. Some 
women reported difficulties coping with specific side effects of treatment. Fatigue and physical 
discomfort were commonly described soon after surgery. At least one woman regretted 
choosing mastectomy, and attributed a loss of confidence to having had the procedure.38 
Results for Key Question 2 – Effects of Labeling 
 Some studies compared psychosocial outcomes in women with DCIS to women with 
EIBC after controlling for treatment modalities. These studies consistently found no difference, 
or small non-significant differences, in psychosocial outcomes (Evidence Table 3). Outcomes 
assessed in this way included: overall psychological distress, fear of recurrence, risk perception, 
generic quality of life, and breast cancer-specific quality of life. 
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Qualitative Studies 
The qualitative studies asked women to broadly discuss their feelings about their 
condition. Kennedy et al. included women who had not yet been treated. Women consistently 
recalled being “shocked” by the diagnosis of DCIS, and described confusion about whether or 
not they had cancer. Women were often relieved by the good prognosis, but had difficulty 
reconciling the need for drastic treatments for a condition that is supposedly not serious. Some 
women who had been diagnosed but not yet treated described lying awake in bed at night, 
unable to stop worrying about their disease. After treatment, women had varying degrees of 
concern about ongoing risk. One woman described difficulty with discrimination from insurance 
companies and having to take time off work.38 
Risk Factors for Poor Psychosocial Outcomes 
 Independent of treatment modality and other potential confounders, lower 
socioeconomic status (SES) appears to put women at risk of poor adjustment to DCIS 
diagnosis. These low SES women were more likely to experience intrusive thoughts or 
depression nine months after diagnosis, after controlling for baseline depression and anxiety.  
One cohort study found an association between higher risk perception and more anxiety and 
intrusive thoughts.40 
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Evidence Table 3. Summary of Results and Strength of Evidence 
Key Question 1. Psychosocial Effects of Diagnosis and Treatment 
Outcome Studies Key Findings Risk of Bias Consistency Directness Precision 
Strength of 
Evidence 
Anxiety 
1 fair quality    
cohort study 
~10% prevalence in first year 
Non-significant decrease over time 
Medium 
N/A         
(single study) 
Direct Imprecise Low 
Depression 
2 cohort studies,  
1 good and 1 fair 
Bailey (good): No difference, controls vs. patients. 
~10% prevalence in DCIS in first year by CES-D. 
Partridge (fair):                                         
Prevalence consistently 2% by HADS 
Medium Inconsistent Direct Imprecise Low 
Intrusive 
Thoughts 
1 fair quality    
cohort study 
53% prevalence at enrollment 
31% at 18 months 
Medium 
N/A         
(single study) 
Direct Precise Moderate 
Body Image 
1 fair quality 
cohort study 
BCT slightly better than Mastectomy 
No difference by stage 
Medium/High* 
N/A         
(single study) 
Direct Imprecise Insufficient 
Sexual 
Problems 
1 fair quality 
cohort study 
More sexual problems in DCIS and EIBC vs. 
controls at enrollment (non-significant)  
2 years after mastectomy vs. baseline, 2.7 times 
more likely to report sexual problems  
Medium 
N/A         
(single study) 
Direct Imprecise Low 
Fear of 
Recurrence 
1 cross-sectional 
study, fair quality 
29% at least moderate FCR at 2 years 
May be higher in Stage IIA  
High 
N/A         
(single study) 
Direct 
Precise, 
(imprecise for 
comparisons 
by stage) 
Low 
Risk 
Perception 
1 fair quality 
cohort study 
>50% believe likelihood of DCIS and/or invasive 
recurrence is at least moderate 
Persistent at 18 months 
Medium/High* 
N/A         
(single study) 
Indirect Precise Insufficient 
Quality of Life 
3 cohort studies,  
2 good, 1 fair 
Jeffe (good):  
Clinically important, lower QOL for DCIS and 
EIBC at 7 wk. vs. controls. EIBC > DCIS at 6 mo. 
Nekhlyudov (good): 
Clinically significant declines in social function 
and mental health more likely in first 6 months 
Partridge (fair):  
Change over time varies by domain 
Low 
Consistent 
(inconsistent 
after 6 months) 
Direct 
Precise 
(variable 
precision after 
6 months) 
Moderate/Low† 
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Key Question 2. Psychosocial Effects of Labeling, Independent of Treatment 
Outcome Studies Key Findings Risk of Bias Consistency Directness Precision 
Strength of 
Evidence 
Depression 
1 fair quality 
cohort study 
Mean CES-D 9.84 (SD 9.22) at enrollment 
Low SES associated with depression at 9 months 
Medium 
N/A         
(single study) 
Direct Imprecise Low 
Intrusive 
Thoughts 
1 fair quality 
cohort study 
Mean REIS 15.86 (SD 14.05) at enrollment 
Low SES associated with intrusive thoughts at 9 
months 
Medium 
N/A         
(single study) 
Direct Imprecise Low 
Psychological 
Distress 
1 fair quality 
cohort study 
Non-significant trend toward more distress in 
EIBC than DCIS throughout the first year 
Medium 
N/A         
(single study) 
Direct Imprecise Low 
Fear of 
Recurrence 
1 cross-sectional 
study, fair quality 
Stage I vs. DCIS: no difference in FCR at 2 years 
Stage II with greater FCR than DCIS at 2 years 
Medium 
N/A         
(single study) 
Direct Imprecise Low 
Risk 
Perception 
2 fair quality 
cohort studies 
Liu: No significant difference by stage            
DCIS women more likely to overestimate risk 
Partridge: Higher risk perception associated with 
more intrusive thoughts and anxiety 
Medium 
N/A                 
(the 2 studies 
ask different 
questions) 
Indirect Precise Low 
Quality of Life 
3 studies,            
1 fair cohort,        
1 good cross-
sectional, 1 fair 
cross-sectional 
No clinically significant differences in QOL by 
stage, throughout the first year 
Medium Consistent Direct Precise Moderate 
 
Abbreviations: DCIS, ductal carcinoma in-situ; EIBC, early invasive breast cancer; CES-D, center for epidemiologic studies depression scale; HADS, hospitalized anxiety and 
depression scale; BCT, breast-conserving therapy; FCR, fear of cancer recurrence; QOL, quality of life; SES, socioeconomic status; wk., weeks; mo., months; RIES, revised 
impact of event scale; SD, standard deviation 
* Risk of bias for these outcomes depends on the assessment of internal validity of single studies that subjectively might be considered either poor or fair (Evidence Table 4) 
†Moderate strength of evidence for clinically significant QOL effects of DCIS diagnosis and treatment in the first 6 months. Strength is limited by estimates being based largely on 
the 7 week assessment in Jeffe et al., with no pre-diagnosis assessment. Low strength of evidence that quality of life improves more quickly in women with DCIS than EIBC, and is 
approximately normal after one year, given inconsistencies between studies and QOL domains. 
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Discussion   
 This review systematically assesses what is known about the psychosocial harms of 
ductal carcinoma in situ diagnosis and treatment. Chief findings include clinically significant 
decreases in quality of life in the first six months after diagnosis, with intrusive thoughts and fear 
of recurrence commonly persisting at least 18-24 months. Quality of life more than six months 
from diagnosis appears to be approximately equal to healthy controls. 
 The strength of evidence regarding other psychosocial outcomes is low or insufficient. 
By some generic measures, psychological distress appears to be no different in women with 
DCIS as compared to healthy controls. Other studies show similar levels of distress in women 
with DCIS as compared to women with early invasive cancers, but do not include healthy 
controls. Low SES women may be at increased risk of poor adjustment to the diagnosis. 
Women treated for DCIS consistently overestimate their risk of DCIS recurrence and 
development of invasive cancer.  
What Does This Review Add? 
 The previous review by Ganz did not systematically assess the validity of individual 
studies or the strength of the overall evidence.7 That review relied largely on null findings of 
studies comparing DCIS to EIBC, several of which we rated as poor quality, to conclude that 
women with DCIS experience substantial psychological distress. 
 We included eleven articles describing an additional four studies that were not included 
by Ganz. The addition of a good quality prospective cohort study (7 articles, most recently Jeffe 
et al.) is particularly important because it demonstrated clinically important differences in generic 
quality of life in women soon after diagnosis compared to healthy controls. It is clear from this 
study that psychosocial harms are most significant in the weeks to months following diagnosis.  
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Generic vs. Specific Measures 
 Differences in generic quality of life disappeared after six months, but generic measures 
may have insufficient sensitivity to detect important differences in psychological distress. A low 
prevalence of anxiety disorders or clinical depression, for example, does not preclude clinically 
important levels of distress. Though prevalence of these psychiatric disorders appears to be 
10% or less, more than 30% of women experience at least moderate breast cancer-specific 
intrusive thoughts and fear of recurrence long after their diagnosis.  
Labeling vs.Treatment 
The majority of studies examined women after they have completed treatment for DCIS. 
Therefore, they tell us primarily about the cumulative effects of the cascade of DCIS diagnosis 
and treatment (KQ1). Most women with DCIS experience the entire series of events from 
positive mammogram and biopsy to surgical treatment, follow-up, and possibly ancillary 
treatments or re-excisions.54 The effects of the entire cascade may be relevant to individual and 
policy-level decisions about breast cancer screening. Identifying cumulative psychosocial harms 
in these women also illustrates a need for individual psychosocial support. 
A more careful examination of the specific causes of psychosocial harms might allow 
interventions to be tailored to the cause of the problem.  As such, we felt it was important to ask 
specifically whether harms are due to labeling effects or treatment effects (KQ2). 
Certain harms, such as poor body image and sexual dysfunction, are often considered 
among potential effects of breast cancer treatment. Results were consistent with the expectation 
that these outcomes would vary more by treatment modality than by stage of breast disease. 
Overall, few studies have examined the effects of labeling in DCIS. The qualitative studies 
provide perhaps the most direct evidence of the effects of labeling. Lying awake at night 
worrying about your disease, even before being treated, is a clear effect of labeling.38 These 
qualitative studies, though, do not indicate the prevalence these effects.  
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Other studies provide indirect evidence of labeling. Certain outcomes, such as intrusive 
thoughts or fear of recurrence, might be conjectured to be attributable to labeling rather than 
treatment. Studies that control for treatment and find no psychosocial differences among women 
with DCIS compared to women with EIBC may indicate that labeling effects do not differ 
between these groups. However, none of these studies tell us definitively about the burden of 
labeling in DCIS relative to women who are not labeled. It is unclear if psychosocial distress in 
women with DCIS is due primarily to invasive treatments, or if the burden of having “cancer” 
contributes significantly. The distinction between labeling and treatment effects is discussed 
further in Appendix D. 
Limitations of This Review 
Limited Set of Potential Harms 
This review examined only a subset of the potential harms of DCIS diagnosis and 
treatment. For example, effects of labeling might go beyond the outcomes that we included in 
this review. It is challenging to search for studies that examine labeling effects because there is 
no MeSH term for this concept. We outlined an initial set of hypothetical psychosocial outcomes 
for our search strategy, but certain outcomes not specifically included in our search qualified for 
inclusion, while other potentially relevant harms were excluded. 
A woman with “cancer” might experience psychological distress specifically around the 
time of her follow-up care and future mammograms. She might suffer financial losses due to 
missed days of work for follow-up care. Insurance companies might discriminate against her for 
having a pre-existing condition. She may change her behavior in ways that may be beneficial or 
detrimental to her health. The amount of distress due to labeling could affect whether she 
decides to get a mastectomy or wide local excision. Other potential health behavioral changes 
include altered frequency of mammograms or hyper-vigilance about self-breast exams. Her 
spouse and her children may also be affected by knowing that she has cancer. The included 
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studies did not report any of these outcomes (except for the one woman in Kennedy et al. who 
described insurance discrimination), but we did not search specifically for them.  
Imperfect Internal Validity Assessment 
 Internal validity assessment necessarily involves a level of subjectivity. We combined 
objective and subjective elements of appraisal and discussed among multiple reviewers to 
standardize the process, but the final rating of good, fair, or poor determined which studies are 
ultimately included in the review. Other methods might have reached a different conclusion 
regarding any particular study. When in doubt, we tried to err on the side on including more 
studies. None of the studies excluded for poor quality would have significantly changed our 
conclusions had they been included.  
Exclusion of Studies of Invasive Cancer 
 We limited this review to studies that report psychosocial outcomes specifically for 
women with DCIS. There are many similarities between DCIS and early invasive cancers, so in 
some cases it may reasonable to extrapolate what we know about women living with invasive 
cancers to women with DCIS.  
Women with invasive cancers are more likely to receive chemotherapy, hormone 
therapy, and axillary lymph node dissection, all of which appear to have the potential to affect 
quality of life. However, a woman with DCIS is likely to experience the same treatment effects 
as a woman with EIBC who is treated identically. Randomized controlled trials of mastectomy 
versus BCT, for example, might tell us a lot about the effects of mastectomy for DCIS. We did 
not review invasive cancer studies in part because we wanted to know about the literature 
specific to DCIS, and in part because of limited resources.  
 The invasive breast cancer literature might also tell us indirectly about labeling in DCIS. 
Although we did not systematically assess its validity, the study by Hegel et al. appears to 
demonstrate substantial labeling effects in women with early invasive breast cancers. We might 
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use studies like this one, in conjunction with studies showing no differences in labeling between 
DCIS and EIBC, to draw conclusions about labeling in DCIS. However, this line of reasoning is 
too indirect to allow for definitive conclusions about labeling in DCIS. 
Limitations of the Evidence 
Most psychosocial outcomes we identified have been considered by only one or two 
studies that met eligibility criteria. The majority of studies include substantial threats to internal 
validity, with only three studies meeting our criteria for good quality. 
Several studies used relatively small sample sizes, and none of them reported a priori 
power calculations, increasing the likelihood of type II error. Without power analyses, we cannot 
judge whether small, non-significant differences between groups might represent random 
variation or potentially underpowered studies. Multiple statistical comparisons (3/6 observational 
studies) increase the chance that statistically significant associations are actually due to chance 
(type I error). Inadequate description of participant characteristics by stage (3/6 observational 
studies) introduces the potential for selection bias. Some measures, especially those used to 
assess risk perception, were not previously found to be valid and reliable. We did find some 
outside evidence of the validity of similar risk perception measures.55 
Some studies were cross-sectional or cohort studies with only two time points, limiting 
the conclusions that we can draw about how these harms evolve over time. Other studies 
examined only women with DCIS, or compared to women with EIBC, without comparing to 
healthy controls. Lack of healthy controls or pre-diagnosis assessment significantly limits the 
directness of evidence regarding the impact of DCIS.  
Evidence regarding KQ2 and KQ3 was particularly limited. Only one qualitative study 
provided direct evidence of labeling effects by assessing women between diagnosis and 
treatment for DCIS. Both qualitative studies, though, were limited by not reporting the number of 
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women whose experiences reflected each identified theme. We found no studies that met 
eligibility criteria that assessed interventions to improve wellbeing in these women (KQ3). 
Implications for Practice 
 Physicians caring for women with DCIS should be aware that these women are likely to 
experience decreased quality of life in the first six months after diagnosis, and are likely to 
continue to worry about the condition even years later. These women may benefit from 
psychosocial support, but we found no evidence regarding specific interventions that have been 
shown to be helpful.  
Specifically, it remains unclear to what degree labeling these women with a cancer 
diagnosis is responsible for psychosocial harms. Yet given that women seem to drastically 
overestimate their future risk, efforts to educate women about their low risk of future morbidity 
and mortality from breast cancer may be appropriate. While not reviewed here, there is also 
evidence that women of screening age have little knowledge of DCIS, and would like to know 
more about it before deciding to be screened.56,57 
Implications for Research 
Overall, many gaps in knowledge remain. We found some evidence of labeling effects 
with DCIS; but the frequency and burden of these harms, particularly relative to the harms of 
treatment, remain unclear. Given that DCIS represents about 20% of all breast cancers, and 
that prognosis and treatment of DCIS differ from invasive cancers, further research of 
psychosocial harms specific to women with DCIS is warranted. 
Future Studies 
Additional good quality longitudinal studies are needed to clarify the nature and burden 
of psychosocial harms in women with DCIS. These studies should define a priori hypotheses, 
and be appropriately powered to test these hypotheses. Development and use of validated 
disease-specific instruments, with clearly defined minimally important differences, would also 
 36 
 
help move the field forward. Appropriate comparators include pre-diagnosis assessments (not 
recalled) or screen-negative women. 
These studies might be conducted as part of larger prospective cohort studies of harms 
in women undergoing screening by mammogram. Such a study might examine psychosocial 
outcomes at multiple points along the screening cascade to investigate the impact on wellbeing 
of screening and biopsy, though DCIS or invasive cancer diagnosis and treatment. Studies 
should include time points prior to screening, and between diagnosis and treatment.  
Serial qualitative assessments might be incorporated, or performed as separate studies, 
to further describe the nature of harms experienced by these women over time. Future 
qualitative studies might include quantitative summaries of the number of women whose 
experiences reflect each reported theme.  
Interventions to Improve Wellbeing 
 Given the clinically significant decrease in quality of life early after DCIS diagnosis, 
studies investigating interventions to improve wellbeing are warranted. These might include both 
preventive and therapeutic efforts.  
 Studies should investigate whether women with DCIS benefit from general support 
strategies such as counseling or support groups. A better understanding of the root causes of 
psychosocial harms might allow for more targeted interventions. Given what we know from 
invasive cancer studies, ongoing efforts to minimize the invasiveness of surgery and number of 
ancillary treatments might improve outcomes in DCIS. It remains somewhat unclear whether 
labeling effects should be targeted, but it might be reasonable to evaluate whether better 
education and risk communication strategies have the potential to decrease cancer-specific 
intrusive thoughts and fear of recurrence. An RCT might be designed to test whether not using 
the word cancer to describe DCIS actually decreases anxiety.  
Establishing an Analytic Framework 
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 An analytic framework should be developed and empirically tested to clarify the 
relationship between DCIS knowledge, risk perception, wellbeing, and behavior. Studies to date 
demonstrate associations without establishing causal relationships. It is unclear whether 
improved understanding of the low risk of DCIS would decrease risk perception and improve 
wellbeing. Partridge et al. demonstrate an association between overestimation of risk and 
distress, but it is not clear that one causes the other.40 
Early labeling effects might be particularly important if they alter a woman’s treatment 
choice. It appears that women who fear cancer more are more likely to opt for mastectomy.58 
Mastectomy might, in turn, have a substantial psychosocial impact. Studies should perform 
mediation analyses and establish temporal relationships between each of these variables.  
Conclusions 
Women diagnosed with DCIS experience decreased quality of life early after treatment, 
and more persistent breast cancer-specific intrusive thoughts and fear. It is important to 
understand potential short-term and long-term harms associated with DCIS given that more 
than 50,000 women are diagnosed in the U.S. each year. Many of these women, perhaps more 
half, have no chance of benefiting from the diagnosis or treatment. The possibility of these 
harms may play a role in the decision to screen for breast cancer for some women.  
Future studies should include prospective cohort studies and serial qualitative studies 
that assess psychosocial wellbeing at multiple points along the DCIS diagnosis and treatment 
cascade. The relationship between knowledge, risk perception, wellbeing, and behavior should 
be clarified. A better understanding of these psychosocial harms would facilitate targeted efforts 
to improve wellbeing women with DCIS. 
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Appendix A. Introduction 
Definition of Psychosocial 
Our definition of psychosocial parallels a definition outlined by Patricia Ganz in a 
narrative review of psychosocial distress in breast cancer.59 Ganz specifies that these aspects 
include a “broad range of affective and cognitive concerns”, beyond clinical depression and 
anxiety disorders. Like Ganz, we consider psychosocial outcomes to include cancer-specific 
aspects such as risk perception, fear of recurrence, and intrusive thoughts, as well as generic 
measures of worry, anxiety, and depression. We exclude purely physical symptoms, but include 
distress that might arise from these symptoms. For example, we exclude “vaginal dryness” or 
“pain during intercourse”, but include “sexual dissatisfaction”. Finally, we include relevant 
domains of global quality of life assessments. 
DCIS: Definition and History 
Ductal Carcinoma in Situ (DCIS) is a histologic diagnosis that indicates the presence of 
a proliferation of mammary duct epithelium. The epithelial cells do not invade beyond the ductal 
basement membrane into surrounding tissues.  DCIS falls along a spectrum of breast epithelial 
proliferation, between atypical hyperplasia and invasive breast cancer.  
Ductal carcinoma in situ is heterogeneous in its histologic and clinical features.60 Many cases of 
DCIS diagnosed by mammography represent a single, small lesion (<1cm), but tumors can also 
be larger or multicentric. It is typically classified as having low, medium, or high grade 
cytonuclear features. A histologic subtype is assigned based on architectural pattern (comedo, 
cribiform, and others).61 Comedo necrosis and microcalcification may or may not be present. 
Histologic architecture, nuclear grade, and tumor size influence the likelihood of development of 
invasive breast cancer after DCIS treatment. 
The condition was first described in the early 20th century by Dr. Joseph Bloodgood.24 
Early reports of DCIS referred to the diagnosis as “comedo carcinoma” due to the high grade 
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“comedo” histology observed in many specimens. Until the 1980’s, DCIS was a rare diagnosis 
made primarily on investigation of a palpated breast mass or nipple discharge. Today, more 
than 90% of the 54,000 annual diagnoses are made by mammographic detection, usually of 
microscopic calcifications, in women who have no palpable lump and are otherwise 
asymptomatic.62 
DCIS: Ancillary Treatments 
In patients undergoing mastectomy for DCIS, a sentinel lymph node biopsy may be 
performed in case invasive disease is found.63 Axillary dissection is not recommended. Women 
with DCIS do not require chemotherapy. Some women with estrogen-receptor positive DCIS are 
treated with adjuvant hormone therapy to decrease the risk of developing invasive cancer. 
Breast Cancer Screening: The Balance of Harms and Benefits 
Harms may be associated with each step of the screening cascade, including the 
screening test, workup, diagnosis, and treatment. They may be physical, psychological, social, 
or financial.  
 If a hypothetical cohort of one thousand 50-year-old women is screened by annual 
mammography for ten years, approximately one will avoid death from breast cancer.28 Ten 
thousand mammograms will be performed. Between 200 and 500 will experience false alarms, 
of which 50 to 200 will go on to biopsy. False positives have been shown by meta-analysis to 
cause small but significant amounts of distress.32 Between two and ten women will be 
overdiagnosed, and experience the harms of diagnosis and treatment without the possibility of 
benefiting. Between five and fifteen women will experience diagnosis and treatment earlier in 
their life than they would have without screening, without changing their prognosis. These data 
are shown in Figure 2. 
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Figure 2.  One Thousand 50-year-old Women Screened Annually for 10 years 
  
 
 
 
 
 
 
 
 
 
 
 
Note: The numbers represented in this figure are not intended to exactly represent the number of women that would 
experience each outcome. They are derived from Welch and Black’s article which gives a range for each outcome.
28
  
We present the mean of the upper and lower limits of the range, recognizing that these numbers are uncertain and 
may underestimate or overestimate the actual number of women that would experience each outcome in such a 
hypothetical cohort. For example, Welch and Black suggest between two and ten women would be overdiagnosed, 
so we show six women overdiagnosed.  
 
 Just as it is important to consider the range of potential harms of screening, it is also 
important to consider the range of potential benefits. Although a decrease in morbidity and 
mortality is the ultimate goal of any screening program, there may be other potential benefits. 
One of these is posttraumatic growth (PTG) after cancer diagnosis. PTG occurs when patients 
perceive positive changes as a result of their cancer experience. Patients often describe viewing 
their place in the world differently after being diagnosed with cancer. The experience of PTG 
might protect women from potential adverse consequences of diagnosis and treatment, which 
might translate to improved psychosocial outcomes including quality of life.64 However, cancer 
survivors who describe PTG do not appear to consistently experience improved quality of life.65  
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Intersection of Psychological and Physical Harms   
 The relationship between physical and psychological outcomes in breast cancer patients 
is complex. Physical side effects, such as painful lymphedema, appear to impair quality of life. 
Alternatively, patients who are anxious or depressed might subjectively report more pain and 
other treatment effects. In the case of lymphedema, some studies have standardized symptom 
assessment by corroborating subjective symptom measures with objective indicators of 
treatment outcomes, supporting the hypothesis that the symptoms are causing the poorer 
quality of life.66 More often, the causal relationship between psychosocial outcome constructs 
and physical symptoms has not been worked out.  
 According to Leventhal’s Common Sense Model of Self-Regulation, individuals 
diagnosed (labeled) with a condition construct internal cognitive and emotional representations 
of that illness that influence the process of adjustment.67 There is some evidence that illness 
perception at diagnosis can affect future physical and psychological outcomes in breast cancer 
patients.68 
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Appendix B. Methods 
 
Search Strategies 
 
MEDLINE (Pubmed) 
 
Step Search Terms Number of Articles 
1 carcinoma, intraductal, noninfiltrating.shii  
2 ductal carcinoma in situ  
3 1 or 2 9563 
4 breast neoplasms.sh  
5 breast cancer  
6 4 or 5   
7 in situ  
8 noninvasive  
9 stage 0  
10 stages 0  
11 7 or 8 or 9 or 10  
12 6 and 11 13516 
13 3 or 12 18374  
14 anxiety  
15 depression  
16 distress  
17 worry  
18 fear  
19 perceived risk  
20 risk perception  
21 quality of life  
22 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21  
23 13 and 22 277 
24 Limit to publication between January 1, 1990 to April 20, 2012 259 
 
CINAHL, PsyINFOo, and Cochrane Library 
 
We searched the CINAHL, PsycINFO, and Cochrane Library databases using the following 
search string: ("ductal carcinoma in situ" OR DCIS OR ("breast cancer" AND ("in situ" OR 
noninvasive OR "stage 0" OR "stages 0"))) AND (anxiety OR depression OR distress OR worry 
OR fear OR "perceived risk" OR "risk perception" OR "quality of life"). We limited these 
searches to articles published between January 1, 1990 (or the earliest date searchable by the 
database) to April 20, 2012. The Cochrane Library was search was limited to title, abstract or 
keywords. CINAHL yielded 58 results, PsycINFO yielded 43 results, and the Cochrane Library 
yielded one result. After removal of 71 duplicates, our searches yielded 290 unique articles.  
                                                          
ii
 .sh denotes a Medical Subjects Heading (MeSH term) 
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Study Assessment Tools  
Study Internal Validity (Risk of Bias) Review Form for Observational Studies and RCTs)iii 
REF #    _______ Author:  ____________ Year: _______ Reviewer: ________ 
 
Title: ____________________________________________________________________________ 
 
Question Response Criteria Comments 
Internal Validity  
1.  Method of Randomization 
(RCT only)  
 
Good         Computer generated random 
allocation.  
 
 
Fair           Flipped coin  
 
Poor            Pseudo randomization (ie. alternate 
allocation, by days of week, etc) or 
randomization approach cannot be 
determined  
 
N/A            Participants not randomized  
 
2. Allocation Concealment 
(RCT only)  
  
Good         Central randomization  
 
 
Fair           Opaque envelopes  
 
Poor            No concealment  
 
N/A             Participants not randomized  
 
3. Nonbiased selection of 
participants and adequate 
description of participants 
Good         No baseline differences (>20% 
qualitatively) among groups. Adequate 
description of participants 
 
 
Fair           Few baseline difference among 
groups, or inadequate description of 
participants  
 
Poor            Multiple differences among groups 
 
N/A              
 
4. Maintenance of 
comparable groups. If 
there is only one study arm 
than consider the overall 
attrition only.  
 
Good         Low attrition (< 20%) and Low 
differential loss (<5%) 
 
 
Fair           Moderate attrition (20-40%) or 
Moderate differential loss (5-15%) 
Poor            High Attrition (>40%) or  
High differential loss (>15%)  
N/A             Cross-sectional, case-control.  
 
                                                          
iii Adapted from Berkman et al33, who drew criteria from the US Preventive Services Task Force, the 
National Health Service Centre for Reviews and Dissemination, the AHRQ’s Evidence-based Practice 
Center Systematic Review Manual, and a report on the quality of observational studies developed 
by the RTI-UNC EPC. 
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5. Independent variable 
measurement.  
May be diagnosis, or other 
variable hypothesized to 
be associated with 
outcomes depending on 
study design.  
Good         Stratified by DCIS, +/-  Stage I, Stage 
II or Stage I & II, by pathologic 
diagnoses. 
Other independent variables (if any) 
valid and reliable. 
 
Fair           No DCIS reporting. Instead lumped 
measurement of Stage 0 breast 
cancer. Other independent variables 
partially validated 
Poor            Inappropriate stratification or non-
validated measures 
6. Outcome measurement  Good         Measure valid and reliable (validated 
scale).  
 
Fair           Some of the above features (partially 
validated scale or adapted from 
validated scale) 
Poor            None of the above features (non-
validated scale) 
7. Outcome measurement 
appropriately applied 
Good         Same measurement applied to each 
group. Measurement at same point in 
time in each group. Outcomes are self-
reported or assessors are blinded if 
appropriate. 
 
Fair           Some of above features 
 
Poor            None of above features 
 
N/A             No comparison group 
8. Appropriate statistical 
testing 
Good         Appropriate analyses for given data 
 
 
Fair           Some tests are appropriate 
 
Poor            Inappropriate statistical tests 
9. Appropriate control of 
confounding 
Okay to not adjust for 
treatment received, since 
one of our questions is 
about the combined effect 
of diagnosis & treatment 
Good         Addressed through matching, 
stratification, multivariate analysis or 
other statistical adjustment 
 
Fair           Some confounders addressed, or list 
of likely potential confounders reported 
and appear similar between groups 
Poor            No consideration of confounding  
 
10. Sample size sufficient  Good         Yes, by power analysis for all 
outcomes reported 
 
Fair           Yes, by power analyses for some 
outcomes. DCIS n>100 in single arm 
study or >50 in multiple arm study 
Poor            No power analyses, DCIS n <100 in 
single arm study, n < 50 in multiple 
arm study 
Overall Assessment 
11. Overall study assessment Good         Conclusions are very likely to be 
correct given degree of bias  
(1-10: at most 2 fair and 0 poor) 
 
Fair           Conclusions are probably correct 
given the degree of bias 
(at most 1 poor) 
Poor            Conclusions aren’t certain because 
bias is too large  
(2 or more poor or one major flaw) 
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Qualitative Study Quality/Credibility Review Formiv 
  
REF #    _______ Author:  ____________ Year: _______ Reviewer: ________ 
 
Title: 
____________________________________________________________________________ 
 
Question Response Criteria Comments 
 
Screening Questions 
 
1.  Clearly formulated 
question and research 
aims 
Yes            Specific research question was 
clearly formulated. Research aims 
described. 
 
 
No              
 
2. Qualitative methodology 
appropriate  
Yes            Clear and compelling justification 
for use of qualitative methods. 
Seeks to illuminate subjective 
experiences of patients with DCIS 
 
No              
 
 
Detailed Questions 
(if yes to #1 and #2) 
 
3. Sampling: Was the 
sampling strategy clearly 
defined and justified? 
Good          Authors clearly describe 
purposeful sampling strategy.  
 Subject characteristics have 
been defined.  
 It is clear what participants 
chose not to take part.  
 Investigators selected an 
appropriate setting and range 
of individuals. 
 
Fair           Some of the above features 
 
Poor            None of the above features 
 
4. Data collection: Was data 
collection appropriate? 
 
Good          Setting is clear and justified 
 Data collection method (focus 
group, interview, etc) is clear 
and justified 
 Form of data collection (video 
tape, audio tape, etc) is 
reliable 
 Methods are explicit (for 
example, if an interview, was 
an interview guide used?) 
 Saturation of data is 
discussed 
 
Fair           Most of the above features 
 
Poor            Few or none of the above features 
 
                                                          
iv Adapted from the Critical Appraisal Skills Programme (CASP) and How to read a paper: Papers that go 
beyond numbers (Greenhaigh)34,69 
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5. Reflexivity: Has the 
relationship between 
research and participants 
been adequately 
considered? 
Good          The researcher has critically 
examined his or her role, 
including potential biases and 
influences.  
 The author describes how 
research was explained to 
participants. 
 
Fair           Some of the above features 
 
Poor            None of the above features 
 
6. Data Analysis: Was 
analysis appropriate and 
rigorous? 
Good          Analysis process is described. 
 Sufficient data is presented. 
 Selected original data 
(quotes) or themes are 
included. 
 Author explains how data or 
themes were selected.  
 Author considers contradictory 
data and/or potential biases in 
selecting data for presentation 
 
Fair           Most of the above features 
 
Poor            Few or none of the above features 
 
7. Findings: Are conclusions 
appropriate and stated 
clearly?  
Good          Conclusions are explicit, and 
appropriate given original 
questions 
 Alternative explanations for 
the results have been 
explored 
 
Fair           Some of above features 
 
Poor            None of above features 
 
Overall Assessment 
8. Overall study assessment Good         Conclusions are very likely 
credible  
(3-7: at most 1 fair and 0 poor) 
 
Fair           Conclusions are probably credible 
(at most 1 poor) 
Poor            Study has poor credibility 
No to #1 or #2. Or questions 3-7 
include 2 or more ‘poor’ 
responses. 
 
Assessment of Strength of Evidence 
 Strength of evidence grade was assigned for each outcome investigated by at least one 
study. The grade was assigned by qualitatively combining assessments of risk of bias, 
consistency, directness, and precision.37 High strength of evidence indicates high confidence 
that the evidence reflects the true effect. We required low risk of bias, and consistent, direct, 
and precise evidence to be considered high strength of evidence. Moderate and low strengths 
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of evidence indicate increasing likelihood that future research would likely change the estimate 
of effect. The evidence is insufficient to estimate an effect if inconsistencies or imprecision are 
not reconcilable, or the evidence is comprised of a single study with substantial risk of bias.  
Risk of Bias, Consistency, Directness, and Precision 
 The risk of bias primarily represents the internal validity of the individual studies. We 
generally considered good quality studies to have a low risk of bias, and fair quality studies to 
have a medium risk of bias. The assessment also incorporates study design. We downgrade the 
risk of bias, for example, if estimates are based largely on cross-sectional data. 
 Consistency is the degree to which each of the studies finds the same effect. 
Consistency is rated as consistent, inconsistent, or not applicable (N/A). To be considered 
consistent, the effect must be in the same direction and of similar magnitude for each study. 
Consistency cannot be evaluated for a single study, so we downgrade the overall strength of 
evidence for outcomes assessed by only one study.  
 Directness indicates the degree to which the evidence relates directly to health 
outcomes. For the purposes of this review, directness relies primarily on the outcome under 
consideration. Outcomes such as risk perception might be considered an intermediate outcome, 
while quality of life, anxiety and depression are more patient-centered.  
 Precision is the degree of uncertainty surrounding an effect estimate, but is difficult to 
define for certain study designs. A clinically significant point estimate whose confidence interval 
includes insignificant values would be considered imprecise. Differences that are not statistically 
significant (p>0.05), are also considered imprecise. We considered null findings to be precise 
only if point estimates were similar between groups and sample sizes were relatively large. We 
considered prevalence estimates to be precise only if the prevalence was substantially higher 
than what might be expected, and sample size was relatively large (for example, 53% of 487  
women with DCIS experiencing at least a moderate degree of intrusive thoughts).
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Appendix C. Results  
List of Included Studies: Comparison to a Previous Review 
 The previous review by Ganz included ten articles published from 1999 to 2010 describing nine unique 
studies. Four of these articles met eligibility criteria for inclusion in this review. Three were excluded for poor 
quality (Bluman70, Rakovitch71, Van Gestel72). Reasons for excluding these studies are described in Table 2. 
Two were excluded because outcomes were assessed more than three years from diagnosis (Amichetti73, 
Casso74), and one was excluded because it focused on physical symptoms (Janz, 200775). 
 We included eleven additional articles describing four additional. The two qualitative studies, and one 
quality of life study (Janz, 2009) were not included by Ganz. Seven articles looking at psychosocial outcomes 
in a single large prospective cohort have been published since the publication of the Ganz Review. The final 
article (De Moor) described additional analysis of a study already included by Ganz (Partridge). 
 Table 2. Studies Excluded for Poor Quality or Credibility 
Study Study Design Primary Reasons for Poor-Quality Rating 
Bluman et al., 
2001
70
 Cross-sectional 
Cross-sectional study with no comparison group and a small sample size (<100). Some 
reported outcomes are valid and reliable, but for these outcomes we are given a sample 
mean or prevalence without any comparison group or analysis of correlates. Other 
outcomes (risk overestimation, cancer worry, concern) include an analysis of correlates, 
but measures of the potential correlates are non-validated. 
Statistical analysis did not account for multiple comparisons or control for potential 
confounders 
Davey et al., 
2011
76
 
Cross-sectional, with a 
qualitative component 
Results are difficult to interpret given the use of non-validated measures and no 
consideration of confounding 
Qualitative methods are inadequately described 
De Morgan et 
al., 2011
77
 
Cross-sectional, with a 
qualitative component 
Cross-sectional study with no comparison group, only a moderate sample size (n=144), 
and no power calculations. Reports on a number of outcomes of interest, but 
hypothesized independent variables and outcomes are both non-validated in most 
cases. Some validated scales were reported, but these results are given as sample 
means or prevalence with no comparison group or analysis of correlates. Statistical 
analysis did not account for multiple comparisons 
Qualitative methods are inadequately described 
Janz et al., 
2011
78
 Cross-sectional 
Results are difficult to interpret given the use of non-validated outcome measures and no 
consideration of confounding 
Rakovitch et 
al., 2003
71
 Cross-sectional 
Results are difficult to interpret given the use of non-validated outcome measures and no 
consideration of confounding 
Van Gestel et 
al., 2006
72
 Cross-sectional 
Results are difficult to interpret given the very small sample size (DCIS n < 50) and no 
consideration of confounding. Some outcome measures are non-validated 
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Table 3. Internal Validity (Risk of Bias) of Included Studies 
Study Design 
Participant 
Selection  
Group 
Maintenance 
Independent 
Variable 
Measurement 
Outcome 
Validity and 
Reliability 
Application of 
Outcome 
Assessment 
Statistical 
Analyses 
Consideration 
of 
Confounding 
Sample 
Size 
Internal 
Validity 
Bailey et 
al., 2010 
Liu et al., 
2010 
Liu et al., 
2010 
Pérez et al., 
2010 
Collins et 
al., 2011 
Liu et al., 
2011 
Jeffe et al., 
2012 
Prospective 
cohort 
Good Good  Good  
Good/Fair/ 
Poor  
Good Good/Fair Good Fair Good/Fair 
Consistent 
recruitment 
strategy  
Controls are 
screen-negative  
Participant 
characteristics 
described 
exhaustively 
Groups similar 
at baseline 
8% attrition at 
2 years 
Differential 
loss < 5% 
DCIS and 
EIBC 
pathology 
verified. 
Include 
validated, 
partially 
validated, and 
non-validated 
measures.  
 
Perceived risk 
is non-
validated 
Appropriate 
 Telephone 
interviews 
Most are 
appropriate 
Some 
analyses 
were post-
hoc with no 
adjustment 
for multiple 
comparisons  
Controls age-
matched 
Controlled for 
selected 
variables 
No power 
analyses 
DCIS:       
n = 184 
EIBC        
n = 365   
Controls   
n = 547 
 Good for 
QOL and 
depression 
(validated), 
and for 
partially 
validated 
measures 
with ‘good’ 
analyses. 
Fair for other 
outcomes 
Janz et al., 
2005 
Cross-
sectional 
Fair  N/A Good Good Good Good Good Fair Good 
All cases of 
DCIS, 20% 
random sample 
of EIBC from 
two SEER sites  
Only treatment 
is described by 
stage 
Cross-
sectional 
Confirmed 
primary DCIS 
or EIBC 
Valid and 
reliable QOL 
measures  
Appropriate 
Written 
surveys 
 
 
Appropriate 
Items of 
interest 
identified a 
priori 
 
 
Controlled for 
appropriate list 
of potential 
confounders 
No power 
analyses 
DCIS:       
n = 555 
Stage I:      
n = 462 
Stage II:     
n = 239 
 
Janz et al., 
2009 
Cross-
sectional 
Fair  N/A Good Good Good Poor Good Fair Fair 
 
Cases of DCIS 
and EIBC from 
two SEER sites 
(also included 
stage III) 
Only 
race/ethnicity 
described by 
stage 
 
Cross-
sectional 
Confirmed 
primary DCIS 
or EIBC 
Valid and 
reliable 
quality of life 
measures  
Appropriate 
Written 
(96.5%) or 
telephone 
surveys (3.5%) 
For our 
study 
question, 
stage III 
cancer is   
not an 
appropriate 
reference 
group 
Controlled for 
appropriate list 
of potential 
confounders 
No power 
analyses 
DCIS:       
n = 272 
Stage I:    
n = 593 
Stage II:    
n = 459 
Stage III:   
n = 168 
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Study Design 
Participant 
Selection  
Group 
Maintenance 
Independent 
Variable 
Measurement 
Outcome 
Validity and 
Reliability 
Application of 
Outcome 
Assessment 
Statistical 
Analyses 
Consideration 
of 
Confounding 
Sample 
Size 
Internal 
Validity 
Lauzier et 
al., 2009 
Prospective 
cohort 
Good Good Poor Good Good Good Good Fair Fair 
Consecutive 
cases at 8 
Quebec 
hospitals 
Participants 
thoroughly 
described 
(refers to 
Lauzier, 2008 
for details) 
3% attrition at 
12 months 
Primary DCIS 
or invasive 
breast cancer  
Stages I-III 
combined, but 
participants not 
receiving 
chemotherapy 
are likely  
stage I or II 
Valid and 
reliable 
outcomes 
measures 
Appropriate 
Telephone 
interviews 
Consistent 
timing 
Appropriate  
 Appropriate 
treatment of 
missing data 
Appropriate 
consideration 
of likely 
confounders 
No power 
analyses 
DCIS:       
n = 107 
Stage I-III:  
n = 693 
 
Nekhlyudov 
et al., 2006 
Prospective 
cohort 
Fair Good Good Good Good Good Good Fair Good 
Participants 
from Nurses’ 
Health Study 
Women with 
DCIS 5 years 
older 
Baseline 
measured up to 
8 years before 
diagnosis 
6% attrition 
from pre-
DCIS to post-
DCIS surveys 
162,691 
controls in 
1992.  
114,218 
completed all 
assessments 
Confirmed 
primary DCIS 
Valid and 
reliable 
quality of life 
questionnaire 
Appropriate 
Self-
administered 
Appropriate 
analyses 
Appropriate 
consideration 
of likely 
confounders 
No power 
analyses 
DCIS:       
n = 510 
No 
cancer:    
n=114,218 
 
Partridge et 
al., 2008 
de Moor et 
al., 2010 
Prospective 
cohort 
Good Good 
Partridge: 
Good 
de Moor: Fair 
Partridge: 
Good/Poor 
de Moor: 
Good 
Fair 
Partridge: 
Fair 
de Moor: 
Good 
Good Fair Fair 
Consecutive 
cases of DCIS, 
tumor registry 
Participants 
thoroughly 
described 
13% attrition 
at 9 months 
20% attrition 
at 18 months  
Dropouts 
lower SES, 
and fewer 
procedures  
Confirmed 
DCIS  
de Moor: SES 
by education 
and ad hoc 
financial status 
question 
Most 
measures are 
valid and 
reliable  
Poor for risk 
perception 
and recalled 
outcomes  
Telephone 
interviews by 
trained 
interviewers 
Enrollment 
could occur 
before or after 
treatment 
Partridge: 
No multiple 
comparisons 
adjustment 
de Moor: 
Mediation 
analysis 
described in 
detail 
Controlled for 
appropriate list 
of potential 
confounders 
No power 
analyses 
DCIS:       
n = 487 
 
 
Note: Randomization and allocation concealment were included in our quality assessment tool, but are not reported here because no RCTs met eligibility criteria. Abbreviations: 
DCIS, ductal carcinoma in-situ; EIBC, early invasive breast cancer; QOL, quality of life; SEER, surveillance, epidemiology, and end results; SES, socioeconomic status. 
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Table 4. Quality (Credibility) of Included Qualitative Studies 
Study Design Sampling  Data Collection Reflexivity Data Analysis Findings Credibility 
De Morgan et 
al., 2002 
Qualitative, 
focus group 
interviews 
Fair Fair Fair Fair Fair Fair 
Clear inclusion 
criteria, and 
description of 
participants 
Convenience sample 
No description of 
non-participants  
Audio-taped, with 
transcripts 
Discussion guide 
used 
No mention of 
saturation 
Some consideration 
of how terminology 
used might affect 
participants 
Coding process is 
described 
Selected quotes and 
themes presented 
No discussion of 
biases or 
contradictory data 
Findings are explicit 
No discussion of 
alternative 
explanations 
 
Kennedy et 
al., 2011 
Qualitative, 
serial 
interviews  
Fair Good Poor Fair Fair Fair 
Convenience sample 
Describe key clinical 
features for each 
patient  
No description of 
non-participants 
Setting and data 
collection methods 
are justified 
Semi-structured 
interview questions 
included in 
publication 
Verbatim 
transcriptions 
Saturation achieved 
No exploration of 
biases 
No description of how 
research was 
explained to 
participants 
Coding process is 
described 
Inductive and 
deductive thematic 
analysis methods are 
outlined 
Selected quotes 
presented 
No consideration of 
biases  
Conclusions are 
explicit 
Little exploration of 
alternative 
explanations 
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Table 5. External Validity of Included Studies 
Study Design Country 
Exclusion Criteria              
(# excluded) 
Participation Rate 
Among Eligibles 
Similarity of Participants 
and Nonparticipants 
Other Relevant Aspects 
(setting, ethnicity, etc.) 
External 
Validity 
Bailey et al., 
2010 
Liu et al., 
2010 
Liu et al., 
2010 
Pérez et al., 
2010 
Collins et al., 
2011 
Liu et al., 
2011 
Jeffe et al., 
2012 
Prospective 
Cohort 
United States 
Neoadjuvant 
chemotherapy 
No English 
Previous breast cancer 
Cognitive impairment 
DCIS and EIBC: 71% 
Controls: 58% 
76% of participants were 
white, vs. 59% of 
nonparticipants (almost all 
others African American) 
61% of participants were 
married, vs. 50% of 
nonparticipants 
Similar in age, cancer stage 
and surgery type 
Recruited at a 
comprehensive cancer 
center and an academic 
medical center 
Fair 
Janz et al., 
2005 
Cross-
sectional 
United States 
Physician concerns 
(<1%) 
Stage III or IV (141) 
Ongoing primary 
treatment (184) 
Previous history of 
breast cancer 
LCIS 
2640 cases identified 
88% initially eligible 
69% of eligibles 
completed written survey 
Participants more likely to be 
younger, white, or less 
advanced stage. Somewhat 
less likely to have had a  
mastectomy 
Excluded women (advanced 
stage or incomplete 
treatment) more likely to be 
younger, African American, or 
never married 
Oversampled African 
American women (19%) 
10% Hispanic 
Included Spanish speaking 
women (4% of sample) 
Excluded Asian women 
Urban areas only 
Fair 
Janz et al., 
2009 
Cross-
sectional 
United States 
Physician refusal (20) 
No English or Spanish 
(17) 
Too ill or incompetent 
(59) 
Denied having cancer 
(23) 
Ongoing primary 
treatment (753) 
Stage IV (23) 
3252 cases identified 
3133 initially eligible 
72% of eligibles 
completed survey 
Excluded late stage or 
incomplete treatment 
Participants less likely to be 
African American (26% vs. 
35%) or never married, and 
more likely to have earlier 
stage cancer or have had 
lumpectomy (54% vs. 63%) 
No difference in age or 
Hispanic ethnicity. 
Oversampled African 
American and Latina 
women 
Urban areas only 
 
Fair 
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Study Design Country 
Exclusion Criteria              
(# excluded) 
Participation Rate 
Among Eligibles 
Similarity of Participants 
and Nonparticipants 
Other Relevant Aspects 
(setting, ethnicity, etc.) 
External 
Validity 
Lauzier et 
al., 2009 
Prospective 
Cohort 
Canada 
Unable to complete 
telephone interview (no 
phone, no French, 
psychological or 
physical limitations) 
Previous history of 
cancer 
1397 breast cancer 
patients 
962 eligible patients 
829 initiated study 
86% (829/962) 
participation 
Not discussed 
Eight hospitals in Quebec. 
Surveys conducted in 
French 
Includes both urban and 
rural hospitals    
Fair 
Nekhlyudov 
et al., 2006 
Prospective 
Cohort 
United States 
DCIS:  
No pre-DCIS survey 
(269) 
Previous cancer (185) 
LCIS or invasion (5) 
Missing data (2) 
Received chemotherapy 
(17) 
Died during study (4) 
Controls: not discussed 
in this publication  
1,023 cases of DCIS 
541 eligible, completed 
pre-DCIS survey 
510 completed post-DCIS 
survey 
Not discussed for entire 
Nurses’ Health Study 
cohort in this publication 
No discussion of 
characteristics of women with 
DCIS who did not complete 
the post-DCIS survey (6%) 
No discussion of controls 
enrolled in 1992 who did not 
complete the 1996 or 2000 
surveys 
Representative sample of 
female nurses 
Data collected between    
1992 and 2000 
Fair 
Partridge et 
al., 2008  
de Moor et 
al., 2010 
Prospective 
Cohort 
United States 
Previous breast cancer 
Evidence of 
microinvasion 
No English or Spanish 
(46) 
DCIS: 64% (487/764) 
816 women with DCIS 
764 initially eligible 
487 completed baseline 
questionnaire 
Participants younger than 
non-participants (p<0.001), 
but means not given 
No other differences found, 
but unclear what other factors 
were considered 
Registry includes academic 
centers and community 
hospitals 
Fair 
 
Note: Determination of external validity involves a degree of subjectivity. The primary reasons for not rating the study as ‘good’ external validity are bolded. Each study population 
was considered to be somewhat representative of all women with DCIS, so no study was considered to have ‘poor’ external validity.  
 
Abbreviations: DCIS, ductal carcinoma in-situ; EIBC, early invasive breast cancer; LCIS, lobular carcinoma in-situ;  
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Evidence Table 4. Complete Results of Included Observational Studies. KQ1: Psychosocial Outcomes after DCIS Diagnosis and Treatment 
Anxiety 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Partridge, 
2008 
Prospective 
cohort 
DCIS only 
HADS 
>10 on 
anxiety 
subscale 
 
Unclear for 
change in 
mean scores 
Enrollment  9 months  18 months 
 
Prevalence (>10): non-significant decrease over time (p=0.06) 
10%  11%  6% 
 
Mean anxiety score: 4.6  5.0  4.1 
Decreased (improved) from baseline to 18 months 
Mean difference -0.46 (95% CI -0.79 to 0.14, p=0.006) 
None in this 
longitudinal 
comparison 
Fair Fair 
Depression 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Bailey, 2010 
Prospective 
cohort 
DCIS, stage I, 
stage IIA 
CES-D 
>15 
suggests 
moderate to 
severe 
depression 
 
Unclear for 
differences 
between 
groups 
Bivariate analysis: proportion of patients (all stages) and controls 
with depressed mood (>15) did not differ significantly 
 
Prevalence, at 7 weeks: 11% DCIS, 16% stage I, 26% stage IIA 
Prevalence at 1 year: 9% DCIS, 9% stage I, 21% stage IIA  
 
Risk of depression in first year, stage I vs. DCIS 
OR 1.55 (95% CI 0.92 – 2.59, p=0.099) 
 
Risk of depression in first year, stage IIA vs. DCIS 
OR 1.82 (95% CI 1.02 – 3.28, p=0.044) 
Age, race, 
employment status, 
social support, history 
of depression, income 
Good Fair 
Partridge, 
2008 
Prospective 
cohort 
DCIS only 
HADS 
>10 on 
depression 
subscale 
 
Unclear for 
change in  
mean scores 
Enrollment  9 months  18 months 
 
Prevalence (>10):  
2%   1%  2% 
Mean depression  score: 
2.4  2.1  2.1 
 
Decreased (improved) from baseline to 18 months 
Mean difference: -0.29 (95% CI 0.54 to -0.14, p=0.43) 
None in this 
longitudinal 
comparison 
Fair Fair 
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Intrusive Thoughts 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Partridge, 
2008 
Prospective 
cohort 
DCIS only 
REIS, DCIS-
specific 
>11 
suggests 
substantial 
intrusive or 
avoidant 
thoughts 
 
Unclear for 
change in 
mean scores 
Enrollment  9 months  18 months 
Prevalence (>11) 
53%  41%  31% 
REIS mean 
15.9  12.9  10 
Intrusion subscale mean 
6.9  5.7  3.8 
Avoidance subscale mean 
9.0  7.2  6.1 
All decreased (improved) over time (p<0.001) 
None in this 
longitudinal 
comparison 
Fair Fair 
Body Image 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Collins, 2011 
Prospective 
cohort 
DCIS, stage I, 
stage IIA 
Newly 
developed 8 
item 
instrument 
Not specified 
Unadjusted body image problems did not differ by stage 
Mean body image problems by surgery type (p<0.001) 
BCT 1.66, Mastectomy 1.75 
Mastectomy with reconstruction: 2.04 
Mean body image problems by stage (p=0.38) 
DCIS 1.79, Stage I 1.71, Stage II 1.86 
None Fair⃰ Fair 
Sexual Problems 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Pérez, 2010 
Prospective 
cohort 
DCIS, stage I, 
stage IIA 
Newly 
developed 9 
item 
instrument 
attractive-
ness and 
interest/ 
enjoyment 
subscales 
Not specified 
At 7 weeks, DCIS and EIBC with more sexual problems (overall 
and subscales) than controls, but differences are non-significant 
Over time, controls became more likely to report sexual problems 
(ORs 1.50 to 2.18, most are significant) 
DCIS and Stage IIA did not change over time 
Over time, Stage I less likely to report problems with 
attractiveness (p<0.05) 
At 2 years patients (all stages) who had mastectomy were 2.7 
times more likely to report sexual problems than at baseline 
Age, marital status, 
body image, BMI, 
sexual activity, 
menopausal 
symptoms, depressed 
mood, anxiety, 
employment status, 
education, race, 
income 
Fair Fair 
 
* Using our assessment tool, this study received only one poor rating (no confounders considered). Subjectively, it might be considered poor quality (or borderline fair quality) given 
the use a partially validated measure and substantial likelihood of confounding  
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Fear of Recurrence 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Liu, 2011 
Cross-
sectional 
DCIS, stage I, 
stage IIA 
CARS 
Score of 3-4 
suggests 
moderate 
fear 
 
Score of 5-6 
suggests 
high levels 
of fear 
At 2 years only 
 
Unadjusted mean FCR: 
DCIS – 1.95 
Stage I – 1.99 
Stage IIA – 2.47 (p<0.001, effect size = 0.46) 
 
Prevalence of at least moderate FCR (>2): 
DCIS – 29% 
Stage I – 26% 
Stage IIA – 39% (p=0.13) 
None Fair Fair 
Risk Perception 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Partridge, 
2008 
Prospective 
cohort 
DCIS only 
Absolute (%) 
and Likert-
scales 
Unclear 
% believing outcome is at least moderately likely 
at enrollment  at 18 months 
 
DCIS in the next 5 year: 54%  50% 
DCIS in lifetime: 68%  63% 
Invasive disease, next 5 years: 39%  38% 
Invasive disease, lifetime: 53% 52% 
DCIS spreading to other places in body: 28%  26% 
 
No change in risk perception over time (p=0.38) 
None in longitudinal 
comparisons 
Fair⃰ Fair 
 
* Using our assessment tool, this study received only one poor rating (non-validated instrument). Subjectively, it might be considered poor quality (or borderline fair quality) given 
the difficulty of interpreting results using this instrument.   
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Quality of Life 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Jeffe, 2012 
Prospective 
cohort 
MOS RAND-
36 
Difference of 
>3-5 points 
QOL in both DCIS and EIBC patients improved over the 2 year 
follow-up. Rate of recovery faster in DCIS than EIBC, but only 
statistically significant for social functioning (p=0.03) 
 
At 7 weeks: 
QOL in DCIS worse than controls, all subscales (each p<0.02) 
QOL in DCIS better than EIBC on physical problems (p=0.002), 
energy/fatigue (p=0.23), and social functioning (p=0.0006) 
At 6 months: 
Only physical functioning was worse in DCIS vs. controls (p=0.01) 
DCIS better than EIBC on physical problems, energy/fatigue, 
social functioning, pain, and general health (each p<0.04) 
At 1 year: 
No differences between DCIS and controls 
DCIS better than EIBC on energy/fatigue (p<0.001)) 
At 2 years: 
No differences between DCIS and controls 
DCIS better than EIBC on physical functioning (p<0.001)           
and general health (p=0.002) 
 
Clinically important differences in QOL observed in both DCIS 
and EIBC compared to controls in the first 6 months, all subscales 
Age, race, education, 
marital status, BMI, 
social support, 
comorbidity, history of 
depression, 
menopausal 
symptoms, hormone 
replacement use 
Good Fair 
 
Nekhlyudov, 
2006 
 
 
Prospective 
cohort 
DCIS vs. 
Healthy 
controls 
MOS SF-36 
Decline of > 
10 points 
Prospective 4 year change, Mean difference 
DCIS (pre vs. post-diagnosis) vs. controls: 
Vitality = -2.06 (p<0.01) 
Social Function: -2.40 (p<0.01) 
Role limitation/emotional: -1.58 
Mental health: -0.36 
 
Odds of clinically significant declines if diagnosis in last 6 months, 
vs. diagnosis >6 month prior  
Social Function: OR 1.78 (31% vs 21%, p<0.05) 
Mental health: OR 2.03 (21% vs 11%, p<0.05) 
Nonsignificant differences in Vitality (OR 1.14) and Role 
limitations/Emotional (OR 1.34) 
Diagnosis year, age, 
BMI, marital status, 
physical activity, 
smoking, alcohol, 
family history, 
cormorbidities, 
menopausal status, 
hormone use 
Adjusted for 
treatment changes 
over time (not 
relevant for DCIS vs. 
controls) 
Good Fair 
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Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Partridge, 
2008 
Prospective 
cohort 
DCIS only 
MOS-SF36 
<50 below 
average on 
mental 
component 
subscale  
 
Unspecified 
for subscale 
domains or 
mean 
differences 
 
Compared to 
same-age 
population 
norms from 
other studies 
Prediagnosis (recalled)  Enrollment  18 months 
 
General health: Worse over time (p<0.001) 
85.1  77.5  70.8 
 
Vitality: Worse over time (p<0.001) 
70.0  59.0  53.1 
Worse than population norms at 18 months 
 
Social function: 90.4  80.4  missing 
 
Role limitation/emotional: Better over time (p<0.001) 
90.4  80.1  89.5 
 
Mental health: Worse over time (p<0.001) 
79.1  75.7  65.9 
Worse than population norms at 18 months 
 
MCS: 52.6  50.2  missing 
None in this 
longitudinal 
comparison 
Fair Fair 
 
Abbreviations: DCIS, ductal carcinoma in-situ; HADS, hospitalized anxiety and depression scale; CES-D, center for epidemiologic studies depression scale; OR, odds ratio; CI, 
confidence interval; RIES, revised impact of event scale; BCT, breast-conserving therapy; EIBC, early invasive breast cancer; CARS, concern about cancer recurrence scale; FCR, 
fear of cancer recurrence; QOL, quality of life; BMI, body mass index; MOS SF-36, medical outcomes study short form health survey; MCS, mental component subscale 
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Evidence Table 5. Complete Results of Included Observational Studies. KQ2: Psychosocial Outcomes Independent of Treatment 
 
Depression 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
De Moor, 
2010 
Prospective 
cohort 
DCIS only 
CES-D 
>15 
suggests 
mild to 
moderate 
depression 
 
Unclear for 
change in  
mean scores 
Sample mean at baseline 9.84 (SD = 9.22) 
 
No cross-sectional association between mean baseline 
depression score and education or financial status 
 
Depression at 9 month follow-up associated with lower 
financial status (p=0.0001). Depression increased in women at 
lowest SES. Social support did not mediate this relationship. 
 
No association between follow-up depression and education. 
History of 
mastectomy, 
History of 
tamoxifen, age, 
marital status, 
employment, race, 
menopausal status, 
comorbidities, DCIS 
grade, comedo 
necrosis 
Fair Fair 
Intrusive Thoughts 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
De Moor, 
2010 
Prospective 
cohort 
DCIS only 
REIS, DCIS-
specific 
>11 
suggests 
substantial 
intrusive or 
avoidant 
thoughts, 
> 25 
suggests 
moderate 
symptoms 
> 43 
suggests 
severe 
symptoms 
unclear for 
change in 
mean scores 
Sample mean at baseline 15.86 (SD = 14.05) 
 
No cross-sectional association between mean baseline intrusive 
thoughts and education or financial status. 
 
Intrusive thoughts at 9 month follow-up associated with 
lower financial status (p=0.0001). Intrusive thoughts increased 
in women at lowest SES. Social support did not mediate this 
relationship. 
 
No association between follow-up intrusive thoughts and 
education. 
History of 
mastectomy, 
History of 
tamoxifen, age, 
marital status, 
employment, race, 
menopausal status, 
comorbidities, DCIS 
grade, comedo 
necrosis 
Fair Fair 
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Psychological Distress 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Lauzier, 
2009 
Prospective 
cohort 
DCIS, non-
metastatic 
invasive 
breast cancer 
PSI 
Effect size of 
>0.5 
1 month  6 months  1 year 
 
DCIS Mean PSI (higher indicates more distress): 
22.2  20.4  19.5 
Invasive, no chemotherapy: 
22.8  22.7  22.1 
Invasive and chemotherapy: 
25.9  23.7  21.2 
 
Effect size (invasive and no chemo vs. DCIS): 
-0.03  -0.13  -0.15 
Effect size (invasive and chemo vs. DCIS): 
-0.21  -0.19  -0.10 
 
No clinically significant effect sizes 
Adjusted for 
radiotherapy, 
hormone therapy, 
and age. 
 
Considered type of 
mastectomy, 
education, civil status, 
comorbidities, 
occupational status, 
income, stressful life 
events, social support 
Fair Fair 
Fear of Recurrence 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Liu, 2011 
Cross-
sectional 
DCIS, stage I, 
stage IIA 
CARS 
Score of 3-4 
suggests 
moderate 
fear 
Score of 5-6 
suggests 
high levels 
of fear 
At 2 years only 
 
Adjusted β: 
DCIS: reference 
Stage I: 0.04 (p=0.44) 
Stage IIA: 0.14 (p<0.01) 
Type of surgery, 
surgical side 
effects,  
chemotherapy, 
radiation, hormone 
therapy, age, race, 
education, marital 
status, family history, 
comorbidities, social 
support, anxiety, 
depression, accuracy 
of perceived risk 
Fair Fair 
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Risk Perception 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Liu, Pérez, 
Schootman, 
2010 
Liu, Pérez 
Aft, 2010 
Prospective 
cohort 
Absolute (%) 
risk of 
recurrence 
Accuracy by 
comparison 
to Adjuvant! 
Online 
estimation 
Not specified 
Before adjustment, perceived risk did not differ between DCIS and 
Stage I; Stage II somewhat greater (p=0.06) 
After adjustment, ordinal-scaled ORs 
DCIS: reference 
Stage I: OR 1.07 (95% CI 0.66-1.72, p=0.79) 
Stage IIA: OR 1.24 (95% CI 0.60-2.57, p=0.56) 
 
Accuracy of risk perception, adjusted 
EIBC: reference 
DCIS overestimation: OR 1.76 (95% CI 1.11-2.79) 
DCIS underestimation OR 0.59 (95% CI 0.39-0.89) 
Type of surgery, 
surgical side 
effects, 
radiotherapy, 
chemotherapy, 
hormone therapy, 
age, race, education, 
marital status, family 
history, disease 
knowledge, social 
support, anxiety, 
depressive symptoms 
Fair Fair 
Partridge, 
2008 
Prospective 
cohort 
DCIS only 
Absolute (%) 
and Likert-
scales 
Unclear 
Logistic regression model 
Higher perceived risk of DCIS spread associated with intrusive 
thoughts (RIES > 11), (OR 4.0, 95% CI 1.5-5.1, p<0.001) 
Higher perceived risk (4 of 5 items) associated with HADS anxiety 
> 10 (OR 3.9-5.3, p = 0.001-0.015) 
Variables considered 
in logistic regression: 
Treatment received 
(including 
mastectomy), 
Treatment 
satisfaction, age, 
race, education, 
marital status, 
employment, financial 
status, comorbidity, 
depression, physician 
specialty, DCIS 
grade, comedo 
necrosis 
Fair Fair 
Quality of Life 
Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Janz, 2005 
 
Cross-
Sectional 
DCIS, Stage 
I, Stage II 
 
 
EORTC 
QLQ-C30 
Health-
related QoL 
QLQ BR-23 
Breast 
cancer-
specific QoL 
>10 point 
difference 
considered 
clinically 
meaningful 
Domains of interest a priori included: 
Functional domains (social, emotional, role), body image, future 
perspective, sexual enjoyment 
 
No clinically meaningful differences by stage 
Stage II worse ‘role functioning’ than Stage 0 (difference 4.6, 
p<0.05). No other statistically significant differences by stage 
Surgical treatment, 
time from treatment, 
other treatments, 
study site, prior health 
status, age, race, 
education, 
employment, income, 
marital status 
Good Fair 
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Study Design Instrument 
Clinical 
Importance 
Results 
Confounders 
Considered 
Internal 
Validity 
External 
validity 
Janz, 2009 
Cross-
Sectional 
DCIS, Stage 
I, Stage II, 
Stage III 
FACT-B Not specified 
Results reported as points different from Stage III (reference 
group). Higher scores indicated better QoL. 
 
Functional Domain: DCIS +2.21; Stage I +1.68; Stage II +0.62 
Emotional Domain: DCIS +0.67; Stage I +0.04; Stage II +0.24 
Social Domain: DCIS -0.96; Stage I -0.19; Stage II +0.02 
Breast Concerns: DCIS +0.86; Stage I +0.27; Stage II -0.55 
 
Only functional domain statistically significant difference 
(DCIS better than stage III, p<0.01) 
Treatment received 
(mastectomy, 
radiation, 
chemotherapy), age, 
race, education, 
employment, marital 
status, family history, 
comorbidities, 
Fair Fair 
Lauzier, 
2009 
Prospective 
cohort 
DCIS, non-
metastatic 
invasive 
breast cancer 
SF-12 MCS 
Effect size of 
>0.5 
Population 
mean is 50 
(SD is 10) 
1 month  6 months  1 year 
 
DCIS Mean  (higher indicates better function): 
46.9  49.9  50.0 
Invasive, no chemotherapy: 
48.1  49.3  49.3 
Invasive and chemotherapy: 
45.9  48.3  50.1 
 
Effect size (invasive and no chemo vs. DCIS): 
-0.12  0.05  0.06 
Effect size (invasive and chemo vs. DCIS): 
0.09  0.15  -0.01 
 
No clinically significant effect sizes 
Adjusted for 
radiotherapy, 
hormone therapy, 
and age. 
 
Considered type of 
mastectomy, 
education, civil status, 
comorbidities, 
occupational status, 
income, stressful life 
events, social support 
Fair Fair 
 
Abbreviations: DCIS, ductal carcinoma in-situ; CES-D, center for epidemiologic studies depression scale; RIES, revised impact of event scale; SES, socioeconomic status; PSI, 
psychiatric symptom index; CARS, concern about cancer recurrence scale; OR, odds ratio; CI, confidence interval; EORTC QLQ-C30, European organization for the research and 
treatment of cancer quality of life questionnaire; QLQ BR-23, breast cancer-specific quality of life questionnaire; FACT-B, functional assessment of cancer therapy-breast; SD, 
standard deviation. SF-12 MCS, medical outcomes study short form mental component summary. 
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Appendix D. Discussion 
Distinction between Labeling and Treatment Effects 
 Just as the relationship between physical and psychological harms can be complex, the 
relationship between effects of labeling and treatment may be equally challenging to sort out. 
We assert that intrusive thoughts and fear of recurrence are likely due, at least in part, to 
labeling. Anyone who is told they have cancer is likely to worry, to some degree, about their 
disease.  
Undergoing treatment for cancer might alleviate or exacerbate that worry. The goal of 
treatment is to reduce morbidity and mortality, so theoretically women might worry less after 
treatment. But one might imagine a woman who has had a mastectomy who is constantly 
reminded of her disease by her physical appearance, or other physical effects, after surgery. In 
this way, treatment modality could certainly exacerbate the amount that women worry about 
breast cancer. Women may also worry more about a condition that is serious enough to warrant 
a treatment like mastectomy, a notion that is supported by the qualitative studies in this review. 
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